L Number	Hits	Search Text	DB	Time stamp
1	4458	((544/406) or (544/407) or (546/114) or (546/280.4) or (546/298) or (546/310) or (546/323) or (548/200) or (548/241) or (548/261) or (548/309) or (548/374.1) or (548/503)).CCLS.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/19 19:28
5	5038	((514/255.06) or (514/301) or (514/344) or (514/352) or (514/359) or (514/365) or (514/336) or (514/379) or (514/403) or (514/354) or (514/350) or (514/394)).CCLS.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/19 19:30
6	8443	(((544/406) or (544/407) or (546/114) or (546/280.4) or (546/298) or (546/310) or (546/323) or (548/200) or (548/241) or (548/261) or (548/309) or (548/374.1) or (548/503)).CCLS.) or (((514/255.06) or (514/301) or (514/344) or (514/352) or (514/359) or (514/365) or (514/336) or (514/379) or (514/403) or (514/354) or (514/350) or (514/394)).CCLS.)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/19 19:30
7	13786	synthas$	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/19 19:30
8	209	((((544/406) or (544/407) or (546/114) or (546/280.4) or (546/298) or (546/310) or (546/323) or (548/200) or (548/241) or (548/261) or (548/309) or (548/374.1) or (548/503)).CCLS.) or (((514/255.06) or (514/301) or (514/344) or (514/352) or (514/359) or (514/365) or (514/336) or (514/379) or (514/403) or (514/354) or (514/350) or (514/394)).CCLS.)) and synthas$	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/19 19:30

C:\STNEXP4\QUERIES\10073307 (method).str





chain nodes :
    11 14 15 16
ring nodes :
    1 2 3 4 5 6 7 8 9 10
chain bonds :
    11-14 14-15 14-16
ring bonds :
    1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10
exact/norm bonds :
    11-14 14-15
exact bonds :
    4-7 5-10 7-8 8-9 9-10 14-16
normalized bonds :
    1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
    containing 1 :

Match level :
    1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS
    12:CLASS 14:CLASS 15:CLASS 16:Atom
Generic attributes :
    16:
    Saturation   : Unsaturated

```
=>
Uploading 10073307 (method).str

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 10:23:38 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   6126 TO ITERATE

 16.3% PROCESSED    1000 ITERATIONS                                 8 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       117830 TO   127210
PROJECTED ANSWERS:             560 TO     1400

L2            8 SEA SSS SAM L1

=> s l1 sss ful
FULL SEARCH INITIATED 10:24:34 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 121427 TO ITERATE

100.0% PROCESSED  121427 ITERATIONS                             421 ANSWERS
SEARCH TIME: 00.00.07

L3          421 SEA SSS FUL L1

=> s l3
L4          109 L3

=> s no-synthas? or (nitric oxide synthas?)
       2898729 NO
         70811 SYNTHAS?
         10759 NO-SYNTHAS?
                 (NO(W)SYNTHAS?)
        129620 NITRIC
       1360444 OXIDE
```

```
          70811 SYNTHAS?
          21065 NITRIC OXIDE SYNTHAS?
                  (NITRIC(W)OXIDE(W)SYNTHAS?)
L5        26163 NO-SYNTHAS? OR (NITRIC OXIDE SYNTHAS?)

=> s l4 and l5
L6            2 L4 AND L5

=> d l6 1-2 bib,ab,hitstr
```

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS
AN 2002:637654 CAPLUS
DN 137:185323
TI Preparation of N-tetrahydronaphthyl (hetero)aranecarboxamides as endothelial **NO synthase** expression upregulators
IN Strobel, Hartmut; Wohlfart, Paulus
PA Aventis Pharma Deutschland Gmbh, Germany
SO PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002064565	A1	20020822	WO 2002-EP1448	20020212
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003022935	A1	20030130	US 2002-73307	20020213
PRAI EP 2001-102851	A	20010213		

OS MARPAT 137:185323
AB Title compds. [I; R1 = H, OH, alkyl; R2,R3 = H or alkyl; R5 = (un)substituted Ph or -heteroaryl; R6R7 = (un)substituted CH:CHCH:CH] were prepd. Thus, prepn. of, e.g., RNHCOC6H4F-4 (R = 1,2,3,4-tetrahydro-2-naphthyl) was described. Data for biol. activity of I were given.
IT **291756-22-4P**, 4-Fluoro-N-(1,2,3,4-tetrahydronaphth-2-yl)benzamide **449181-81-1P**, (R)-N-(6-Bromo-1,2,3,4-tetrahydronaphth-2-yl)-4-fluorobenzamide **449181-83-3P**, (S)-N-(6-Bromo-1,2,3,4-tetrahydronaphth-2-yl)-4-fluorobenzamide **449181-85-5P**, (R)-N-(8-Bromo-1,2,3,4-tetrahydronaphth-2-yl)-4-fluorobenzamide **449181-87-7P**, (S)-N-(8-Bromo-1,2,3,4-tetrahydronaphth-2-yl)-4-fluorobenzamide **449181-89-9P**, (R)-N-(5-Methoxy-1,2,3,4-tetrahydronaphth-2-yl)-4-fluorobenzamide **449181-91-3P**, (S)-N-(5-Methoxy-1,2,3,4-tetrahydronaphth-2-yl)-4-fluorobenzamide **449181-92-4P**, (S)-N-(7-Methoxy-1,2,3,4-tetrahydronaphth-2-yl)-4-fluorobenzamide **449181-94-6P**, (R)-N-(8-Methoxy-1,2,3,4-tetrahydronaphth-2-yl)-4-fluorobenzamide **449181-96-8P**, (R)-3-Dimethylamino-N-[1,2,3,4-tetrahydronaphthalen-2-yl]benzamide **449181-98-0P**, (S)-3-Dimethylamino-N-[1,2,3,4-tetrahydronaphthalen-2-yl]benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-tetrahydronaphthyl (hetero)aranecarboxamides as endothelial **NO synthase** expression upregulators)
RN 291756-22-4 CAPLUS
CN Benzamide, 4-fluoro-N-(1,2,3,4-tetrahydro-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 449181-81-1 CAPLUS
CN Benzamide, N-[(2R)-6-bromo-1,2,3,4-tetrahydro-2-naphthalenyl]-4-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449181-83-3 CAPLUS
CN Benzamide, N-[(2S)-6-bromo-1,2,3,4-tetrahydro-2-naphthalenyl]-4-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449181-85-5 CAPLUS
CN Benzamide, N-[(2R)-8-bromo-1,2,3,4-tetrahydro-2-naphthalenyl]-4-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449181-87-7 CAPLUS
CN Benzamide, N-[(2S)-8-bromo-1,2,3,4-tetrahydro-2-naphthalenyl]-4-fluoro-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449181-89-9 CAPLUS
CN Benzamide, 4-fluoro-N-[(2R)-1,2,3,4-tetrahydro-5-methoxy-2-naphthalenyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449181-91-3 CAPLUS
CN Benzamide, 4-fluoro-N-[(2S)-1,2,3,4-tetrahydro-5-methoxy-2-naphthalenyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449181-92-4 CAPLUS
CN Benzamide, 4-fluoro-N-[(2S)-1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449181-94-6 CAPLUS
CN Benzamide, 4-fluoro-N-[(2R)-1,2,3,4-tetrahydro-8-methoxy-2-naphthalenyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449181-96-8 CAPLUS
CN Benzamide, 3-(dimethylamino)-N-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449181-98-0 CAPLUS
CN Benzamide, 3-(dimethylamino)-N-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD

L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS
AN 1998:2994 CAPLUS
DN 128:22823
TI Preparation of dibenzo[c,f]azonines for use as **NO synthase** inhibitors
IN Nallet, Jean Pierre; Megard, Anne Lise; Dreux, Jacques
PA Laboratoires Hoechst, Fr.
SO Fr. Demande, 49 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI FR 2745812	A1	19970912	FR 1996-2966	19960308
FR 2745812	B1	19980507		
PRAI FR 1996-2966		19960308		

OS MARPAT 128:22823
AB Dibenzo[c,f]azonines I [R1 = H, halogen; R2 = H, OMe, OH; R4 = H, alkyl, acyl] were prepd. for use as **NO synthase** inhibitors. Thus, dibenzo[c,f]azonine II was prepd. via sequential redn., hydrolysis, and intramol. cyclocondensation starting from Et 3-(3-methoxybenzylamino)-4-(3,4-dimethoxyphenyl)-2-butenoate, which was prepd. from the condensation of Et homoveratroylacetate with 3-methoxybenzylamine. Prepd. compds, as well as II, were tested for **NO synthase** inhibition.
IT **199389-50-9P 199389-51-0P 199389-52-1P 199389-53-2P 199389-54-3P 199389-55-4P 199389-56-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of dibenzo[c,f]azonines for use as **NO synthase** inhibitors)
RN 199389-50-9 CAPLUS
CN Benzamide, N-[8-chloro-1,2,3,4-tetrahydro-6,7-dimethoxy-4-(phenylmethoxy)-2-naphthalenyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



← Intermediates !

RN 199389-51-0 CAPLUS
CN Benzamide, N-(8-chloro-1,2,3,4-tetrahydro-4-hydroxy-6,7-dimethoxy-2-naphthalenyl)-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 199389-52-1 CAPLUS
CN Benzamide, N-(1,2,3,4-tetrahydro-4-methoxy-2-naphthalenyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 199389-53-2 CAPLUS
CN Benzamide, 3-methoxy-N-(1,2,3,4-tetrahydro-4-methoxy-2-naphthalenyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 199389-54-3 CAPLUS
CN Benzamide, 3,4-dimethoxy-N-(1,2,3,4-tetrahydro-4-methoxy-2-naphthalenyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 199389-55-4 CAPLUS
CN Benzamide, N-(8-chloro-1,2,3,4-tetrahydro-4-methoxy-2-naphthalenyl)-3-methoxy-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 199389-56-5 CAPLUS
CN Benzamide, N-(8-chloro-1,2,3,4-tetrahydro-4-methoxy-2-naphthalenyl)-3,4-dimethoxy-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



```
=> s endothel?
L7        99457 ENDOTHEL?

=> s l5 (p) l7
L8         7144 L5 (P) L7

=> s l4 and l8
L9            1 L4 AND L8

=> s l9 not l6
L10           0 L9 NOT L6

=> s l4 and l7
L11           3 L4 AND L7

=> s l11 not l6
L12           2 L11 NOT L6

=> d l12 1-2 bib,ab,hitstr
```

L12 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS
AN 2001:31473 CAPLUS
DN 134:100864
TI Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
IN Kania, Robert Steven; Bender, Steven Lee; Borchardt, Allen J.; Braganza, John F.; Cripps, Stephan James; Hua, Ye; Johnson, Michael David; Johnson, Theodore Otto, Jr.; Luu, Hiep The; Palmer, Cynthia Louise; Reich, Siegfried Heinz; Tempczyk-russell, Anna Maria; Teng, Min; Thomas, Christine; Varney, Michael David; Wallace, Michael Brennan
PA Agouron Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 439 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001002369	A2	20010111	WO 2000-US18263	20000630
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	BR 2000012352	A	20020514	BR 2000-12352	20000630
	EP 1218348	A2	20020703	EP 2000-943375	20000630
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003503481	T2	20030128	JP 2001-507809	20000630
	US 6531491	B1	20030311	US 2001-983786	20011025
	US 6534524	B1	20030318	US 2001-983783	20011025
	NO 2001005797	A	20020301	NO 2001-5797	20011128
PRAI	US 1999-142130P	P	19990702		
	US 2000-609335	B3	20000630		
	WO 2000-US18263	W	20000630		

OS MARPAT 134:100864
AB Indazole compds. I [R1 = substituted or unsubstituted aryl or heteroaryl, R3CH:CH, R3N:CH; R2 = substituted or unsubstituted aryl, heteroaryl, Y-X; R3 = substituted or unsubstituted alkyl alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl; Y = O, S, C(:CH2), CO, SO, SO2, alkylidene, NH, N(C1-C8 alkyl); X = substituted or unsubstituted aryl, heteroaryl, NH(alkyl), NH(cycloalkyl), NH(heterocycloalkyl), NH(aryl), NH(heteroaryl), NH(alkoxy), NH(dialkylamide)] and their pharmaceutically acceptable prodrugs, active metabolites, and salts are disclosed. The compds. modulate and/or inhibit the activity of certain protein kinases. In particular, I and pharmaceutical compns. contg. them are capable of mediating tyrosine kinase signal transduction, and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compns. contg. such compds., and to methods of treating cancer and other disease states assocd. with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amts. of such compds. E.g., I [R1 = (E)-3,4-(MeO)2C6H3CH:CH; R2 = 4-HO-3-MeOC6H3] (II) was prepd. from

6-aminoindazole by diazotization and substitution with iodide, protection of the indazole nitrogen with 2,4,6-Me3C6H2SO2Cl, coupling of the regioisomeric mixt. with 4-(methoxymethoxy)-3-methoxybenzeneboronic acid in the presence of dichlorobis(triphenylphosphine)palladium, and deprotection of the indazole moiety and iodination at the 3-position of the indazole. Treatment of the 3-indazolyl iodide with sec-butyllithium, phenyllithium, and DMF, regioselective protection of the indazole with 2,4,6-Me3C6H2SO2Cl, olefination with 3,4-dimethoxybenzyltriphenylphosphonium bromide, deprotection of the indazole, deprotection of the methoxymethyl group, and equilibration of the double bond with iodine gave II. Biol. data on protein kinase inhibition, cell proliferation inhibition, neovascularization inhibition, and i.p. and oral bioavailability, are given.

IT **319470-63-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of combinatorial libraries of aryl-substituted indazole derivs. as modulators and inhibitors of protein kinases in the treatment of tumor growth, cellular proliferation, and angiogenesis)

RN 319470-63-8 CAPLUS

CN Benzamide, 2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L12 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS
AN 2000:335387 CAPLUS
DN 132:334364
TI Preparation of anthranilic acid amides as vascular **endothelial** growth factor receptor inhibitors.
IN Huth, Andreas; Seidelmann, Dieter; Thierauch, Karl-Heinz; Bold, Guido; Manley, Paul William; Furet, Pascal; Wood, Jeanette Marjorie; Mestan, Jurgen; Bruggen, Jose; Ferrari, Stefano; Kruger, Martin; Ottow, Eckhard; Menrad, Andreas; Schirner, Michael
PA Schering Aktiengesellschaft, Germany; Novartis Aktiengesellschaft
SO PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000027819	A2	20000518	WO 1999-EP8478	19991109
	WO 2000027819	A3	20000817		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 19910396	A1	20000907	DE 1999-19910396	19990303
	DE 19910396	C2	20011213		
	BR 9915553	A	20010814	BR 1999-15553	19991109
	EP 1129074	A2	20010905	EP 1999-953967	19991109
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002529452	T2	20020910	JP 2000-580999	19991109
	EE 200100258	A	20021216	EE 2001-200100258	19991109
	NO 2001002245	A	20010710	NO 2001-2245	20010507
PRAI	GB 1998-24579	A	19981110		
	DE 1999-19910396	A	19990303		
	WO 1999-EP8478	W	19991109		

OS MARPAT 132:334364
AB Title compds. [I; A = NR2; W = O, S, H2, NR8; Z = NR10, N, NR10(CH2)q, alkyl, etc.; q = 1-6; AZR1 = tetrahydroisoquinolinyl, indazolyl, 5-chloroindolyl, etc.; R1 = (substituted) aryl, heteroaryl; R2 = H, alkyl; R3 = (substituted) mono- or bicyclic aryl, heteroaryl; R4-R7 = H, halo, (substituted) alkoxy, alkyl, carboxyalkyl; R5R6 = dioxetanyl; R8, R10 = H, alkyl]. Thus, Me N-(4-pyridylmethyl)anthranilate (prepn. given) was stirred with Ph(CH2)3NH2 and Me3Al were stirred in PhMe to give N-(3-phenylprop-1-yl)-N2-(4-pyridylmethyl)anthranilamide. The latter inhibited VEGFR I with IC50 = 0.05 .mu.M.
IT **267891-12-3P 267891-15-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of anthranilic acid amides as VEGF receptor inhibitors)
RN 267891-12-3 CAPLUS
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 267891-15-6 CAPLUS
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



IT **267891-99-6 267892-02-4**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of anthranilic acid amides as VEGF receptor inhibitors)
RN 267891-99-6 CAPLUS
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267892-02-4 CAPLUS
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



```
=> s stimulat?
L13     649441 STIMULAT?

=> s synthas?
L14      70811 SYNTHAS?

=> s l7(p)l13(p)l14
L15       1829 L7(P)L13(P)L14

=> s l15 and l4
L16          0 L15 AND L4

=> s expression?
L17     669265 EXPRESSION?

=> s l15(p)l17
L18        553 L15(P)L17

=> s (nitric oxide) or no
        129620 NITRIC
       1360444 OXIDE
         76339 NITRIC OXIDE
                 (NITRIC(W)OXIDE)
       2898729 NO
L19    2918405 (NITRIC OXIDE) OR NO

=> s l18(p)l19
L20        521 L18(P)L19

=> s l20 and l4
L21          0 L20 AND L4

=> log y
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                              50.07     199.23

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                 ENTRY    SESSION
CA SUBSCRIBER PRICE                              -2.60      -2.60

STN INTERNATIONAL LOGOFF AT 10:41:07 ON 19 MAR 2003
```

C:\STNEXP4\QUERIES\10073307.str





chain nodes :
    11 14 15 16
ring nodes :
    1 2 3 4 5 6 7 8 9 10
chain bonds :
    11-14 14-15 14-16
ring bonds :
    1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10
exact/norm bonds :
    11-14 14-15 14-16
exact bonds :
    4-7 5-10 7-8 8-9 9-10
normalized bonds :
    1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
    containing 1 :

Match level :
    1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS
    12:CLASS 14:CLASS 15:CLASS 16:Atom
Generic attributes :
    16:
    Saturation   : Unsaturated

```
=>
Uploading 10073307.str

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1                STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 14:08:11 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   6110 TO ITERATE

 16.4% PROCESSED    1000 ITERATIONS                                 2 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       117517 TO   126883
PROJECTED ANSWERS:              35 TO      453

L2            2 SEA SSS SAM L1

=> s l1 sss ful
FULL SEARCH INITIATED 14:08:29 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 121050 TO ITERATE

100.0% PROCESSED  121050 ITERATIONS                             319 ANSWERS
SEARCH TIME: 00.00.05

L3          319 SEA SSS FUL L1

=> s l3
L4           60 L3

=> d l4 1-60 bib,ab,hitstr
```

L4 ANSWER 1 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 2002:927418 CAPLUS
DN 138:14052
TI Preparation of thiazoles or oxazoles as selective hPPAR.alpha. agonists for treatment of cardiovascular and related diseases
IN Dumaitre, Bernard Andre; Gosmini, Romain Luc Marie
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002096894	A1	20021205	WO 2002-EP5885	20020529

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI GB 2001-13233 A 20010531
OS MARPAT 138:14052
AB The title compds. [I; R1, R2 = H, alkyl; or R1 and R2 may together with the carbon atom to which they are bonded form a 3-5 membered cycloalkyl ring; X1 = O, S; R3, R4, R8 and R9 = H, halo, Me, OMe; R5 = H, alkyl; or R4 and R5 together form a 3-6 membered cycloalkyl ring; X2 = NH, NMe, O; one of Y and Z is N, and the other is O or S; R6 = (un)substituted Ph, pyridyl (wherein the N is in position 2 or 3), with the provision that when R6 is pyridyl, the N is unsubstituted.; R7 = alkyl, alkylheteroaryl, alkylphenyl, etc., with the proviso that when R1 and R2 are Me, R8 and R9 are H, R5 is H, then R7 cannot be Me or CF3] and their esters, were prepd. E.g., a multi-step synthesis of the acid II which showed EC50 of 1.7 nM in hPPAR.alpha. assay, was given.
IT **477771-91-8P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of thiazoles or oxazoles for the treatment of hPPAR.alpha. mediated diseases)
RN 477771-91-8 CAPLUS
CN Propanoic acid, 2-methyl-2-[[5,6,7,8-tetrahydro-5-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]amino]-2-naphthalenyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)



IT **477771-92-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of thiazoles or oxazoles for the treatment of hPPAR.alpha. mediated diseases)
RN 477771-92-9 CAPLUS
CN Propanoic acid, 2-methyl-2-[[5,6,7,8-tetrahydro-5-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]amino]-2-naphthalenyl]oxy]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

L4 ANSWER 2 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 2002:637654 CAPLUS
DN 137:185323
TI Preparation of N-tetrahydronaphthyl (hetero)aranecarboxamides as endothelial NO synthase expression upregulators
IN Strobel, Hartmut; Wohlfart, Paulus
PA Aventis Pharma Deutschland Gmbh, Germany
SO PCT Int. Appl., 81 pp.
CODEN: PIXXD2

Appl. PCT.

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002064565	A1	20020822	WO 2002-EP1448	20020212
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003022935	A1	20030130	US 2002-73307	20020213
PRAI	EP 2001-102851	A	20010213		

OS MARPAT 137:185323
AB Title compds. [I; R1 = H, OH, alkyl; R2,R3 = H or alkyl; R5 = (un)substituted Ph or -heteroaryl; R6R7 = (un)substituted CH:CHCH:CH] were prepd. Thus, prepn. of, e.g., RNHCOC6H4F-4 (R = 1,2,3,4-tetrahydro-2-naphthyl) was described. Data for biol. activity of I were given.
IT **449181-61-7P 449182-01-8P 449182-04-1P**
449182-07-4P 449182-10-9P 449182-13-2P
449182-16-5P 449182-19-8P 449182-21-2P
449182-23-4P 449182-24-5P 449182-25-6P
449182-26-7P 449182-28-9P 449182-30-3P
449182-32-5P 449182-35-8P 449182-37-0P
449182-39-2P 449182-41-6P 449182-43-8P
449182-45-0P 449182-47-2P 449182-49-4P
449182-52-9P 449182-55-2P 449182-57-4P
449182-59-6P 449182-62-1P 449182-65-4P
449182-67-6P 449182-69-8P 449182-71-2P
449182-74-5P 449182-76-7P 449182-78-9P
449182-81-4P 449182-83-6P 449182-85-8P
449182-88-1P 449182-91-6P 449182-93-8P
449182-95-0P 449182-98-3P 449183-00-0P
449183-03-3P 449183-06-6P 449183-08-8P
449183-10-2P 449183-12-4P 449183-14-6P
449183-16-8P 449183-19-1P 449183-21-5P
449183-23-7P 449183-25-9P 449183-27-1P
449183-30-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-tetrahydronaphthyl (hetero)aranecarboxamides as endothelial NO synthase expression upregulators)
RN 449181-61-7 CAPLUS
CN Formic acid, compd. with N-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]-4-

pyridinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 449181-60-6
CMF C16 H16 N2 O

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 449182-01-8 CAPLUS
CN Formic acid, compd. with 3-amino-N-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]pyrazinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 449182-00-7
CMF C15 H16 N4 O

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 449182-04-1 CAPLUS
CN Formic acid, compd. with 3-amino-N-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]pyrazinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 449182-03-0
CMF C15 H16 N4 O

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 449182-07-4 CAPLUS
CN Formic acid, compd. with 6-chloro-N-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]-3-pyridinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 449182-06-3
CMF C16 H15 Cl N2 O

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 449182-10-9 CAPLUS
CN Formic acid, compd. with 6-chloro-N-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]-3-pyridinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 449182-09-6
CMF C16 H15 Cl N2 O

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 449182-13-2 CAPLUS
CN Formic acid, compd. with 1,2-dihydro-6-methyl-2-oxo-N-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]-3-pyridinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 449182-12-1
CMF C17 H18 N2 O2

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 449182-16-5 CAPLUS
CN Formic acid, compd. with 2-amino-N-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]-3-pyridinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 449182-15-4
CMF C16 H17 N3 O

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 449182-19-8 CAPLUS
CN Formic acid, compd. with 2-amino-N-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]-3-pyridinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 449182-18-7
CMF C16 H17 N3 O

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 449182-21-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-methyl-N-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449182-23-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-methyl-N-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449182-24-5 CAPLUS
CN 1H-Indole-4-carboxamide, N-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449182-25-6 CAPLUS
CN 1H-Indole-4-carboxamide, N-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449182-26-7 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, N-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449182-28-9 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, N-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449182-30-3 CAPLUS
CN 1H-Benzotriazole-5-carboxamide, N-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449182-32-5 CAPLUS
CN 1H-Benzotriazole-5-carboxamide, N-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449182-35-8 CAPLUS
CN Formic acid, compd. with 2-methyl-N-[(2R)-1,2,3,4-tetrahydro-2-
naphthalenyl]-3-pyridinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 449182-34-7
CMF C17 H18 N2 O

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 449182-37-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-methyl-N-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449182-39-2 CAPLUS
CN 5-Thiazolecarboxamide, 2,4-dimethyl-N-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449182-41-6 CAPLUS
CN 5-Thiazolecarboxamide, 2,4-dimethyl-N-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449182-43-8 CAPLUS
CN 1H-Pyrazole-4-carboxamide, 5-methyl-1-phenyl-N-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449182-45-0 CAPLUS
CN 1H-Pyrazole-4-carboxamide, 5-methyl-1-phenyl-N-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449182-47-2 CAPLUS
CN 1H-Pyrazole-4-carboxamide, 1-(4-chlorophenyl)-N-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449182-49-4 CAPLUS
CN 1H-Pyrazole-4-carboxamide, 1-(4-chlorophenyl)-N-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449182-52-9 CAPLUS
CN Formic acid, compd. with 5-methyl-N-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]pyrazinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 449182-51-8
CMF C16 H17 N3 O

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 449182-55-2 CAPLUS
CN Formic acid, compd. with 5-methyl-N-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]pyrazinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 449182-54-1
CMF C16 H17 N3 O

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 449182-57-4 CAPLUS
CN 3-Pyridinecarboxamide, 2,6-dimethoxy-N-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449182-59-6 CAPLUS
CN 3-Pyridinecarboxamide, 2,6-dimethoxy-N-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449182-62-1 CAPLUS
CN Formic acid, compd. with 2-chloro-6-methyl-N-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]-3-pyridinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 449182-61-0
CMF C17 H17 Cl N2 O

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 449182-65-4 CAPLUS

CN Formic acid, compd. with 2-chloro-6-methyl-N-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]-3-pyridinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 449182-64-3
CMF C17 H17 Cl N2 O

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

RN 449182-67-6 CAPLUS
CN 5-Thiazolecarboxamide, 4-methyl-2-phenyl-N-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449182-69-8 CAPLUS
CN 5-Thiazolecarboxamide, 4-methyl-2-phenyl-N-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449182-71-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-amino-4,6-dimethyl-N-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449182-74-5 CAPLUS
CN Formic acid, compd. with 2-amino-4,6-dimethyl-N-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]-3-pyridinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 449182-73-4
CMF C18 H21 N3 O

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 449182-76-7 CAPLUS
CN 5-Thiazolecarboxamide, 2-methyl-N-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449182-78-9 CAPLUS
CN 5-Thiazolecarboxamide, 2-methyl-N-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449182-81-4 CAPLUS
CN Formic acid, compd. with N-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]-5-(trifluoromethyl)thieno[3,2-b]pyridine-6-carboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 449182-80-3
CMF C19 H15 F3 N2 O S

Absolute stereochemistry.



CM 2

CRN 64-18-6

CMF C H2 O2



RN 449182-83-6 CAPLUS
CN 1H-Indole-6-carboxamide, N-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449182-85-8 CAPLUS
CN 1H-Indole-6-carboxamide, N-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449182-88-1 CAPLUS
CN Formic acid, compd. with N-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]-6-(trifluoromethyl)-3-pyridinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 449182-87-0
CMF C17 H15 F3 N2 O

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 449182-91-6 CAPLUS
CN Formic acid, compd. with N-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]-6-(trifluoromethyl)-3-pyridinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 449182-90-5
CMF C17 H15 F3 N2 O

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 449182-93-8 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-methyl-N-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449182-95-0 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-methyl-N-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449182-98-3 CAPLUS
CN Formic acid, compd. with 2-methyl-N-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]-6-(trifluoromethyl)-3-pyridinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 449182-97-2
CMF C18 H17 F3 N2 O

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 449183-00-0 CAPLUS
CN Formic acid, compd. with 2-methyl-N-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]-6-(trifluoromethyl)-3-pyridinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 449182-99-4
CMF C18 H17 F3 N2 O

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 449183-03-3 CAPLUS
CN Formic acid, compd. with 6-cyano-N-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]-3-pyridinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 449183-02-2
CMF C17 H15 N3 O

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 449183-06-6 CAPLUS
CN Formic acid, compd. with 6-cyano-N-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]-3-pyridinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 449183-05-5
CMF C17 H15 N3 O

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 449183-08-8 CAPLUS
CN 1H-Pyrazole-4-carboxamide, 3,5-dimethyl-N-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449183-10-2 CAPLUS
CN 1H-Pyrazole-4-carboxamide, 3,5-dimethyl-N-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449183-12-4 CAPLUS

CN 1H-Pyrazole-4-carboxamide, 1-(4-methoxyphenyl)-5-methyl-N-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449183-14-6 CAPLUS
CN 1H-Pyrazole-4-carboxamide, 1-(4-methoxyphenyl)-5-methyl-N-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449183-16-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]-5-(2-thienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449183-19-1 CAPLUS
CN Formic acid, compd. with N-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]-5-(2-thienyl)-3-pyridinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 449183-18-0
CMF C20 H18 N2 O S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 449183-21-5 CAPLUS
CN 2,1-Benzisoxazole-3-carboxamide, N-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449183-23-7 CAPLUS
CN 2,1-Benzisoxazole-3-carboxamide, N-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449183-25-9 CAPLUS
CN 1H-Pyrazole-4-carboxamide, 1-(3,4-dichlorophenyl)-5-propyl-N-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449183-27-1 CAPLUS
CN 1H-Pyrazole-4-carboxamide, 1-(3,4-dichlorophenyl)-5-propyl-N-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449183-30-6 CAPLUS
CN Formic acid, compd. with N-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]-4-pyridinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 449183-29-3
CMF C16 H16 N2 O

Absolute stereochemistry.



CM 2

CRN 64-18-6

CMF C H2 O2

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 2002:637648 CAPLUS
DN 137:185516
TI Preparation of oxazole derivatives and their use as cytokine inhibitors
IN Naruto, Shunji; Sugano, Yuichi; Tatsuta, Tohru; Burdi, Douglas; Porte, Alexander; Grisostomi, Corinna
PA Sankyo Company, Limited, Japan
SO PCT Int. Appl., 444 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064558	A2	20020822	WO 2002-US4326	20020213

W: AU, BR, CA, CN, CO, CZ, HU, ID, IL, IN, JP, KR, MX, NO, NZ, PH, PL, RU, SG, SK, US, VN, ZA
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR

PRAI US 2001-268771P P 20010214
OS MARPAT 137:185516
AB Title oxazole derivs. [I; X = (un)substituted-aryl, (un)substituted-heteroaryl, (un)substituted-N-contg.-heteroaryl; Y = (un)substituted-aryl, (un)substituted-heteroaryl; R2 = OH, alkoxy, NH2, alkylamino, arylamino, etc.] and pharmacol. acceptable salts thereof, which have activity in inhibiting inflammatory cytokines, particularly IL-4, are prepd. Pharmaceutical compns. comprising title oxazole derivs. I and methods of prophylaxis and treatment of diseases mediated by cytokines, particularly allergic diseases are described. Thus, the title compd. II was prepd. from glycine Et ester hydrochloride, 4-tert-butylbenzoyl chloride, and 4-nitrobenzoyl chloride through hydrogenation, acylation, and amination, and was in vitro tested for inhibition of IL-4 prodn. and cellular viability.
IT **449159-60-8P 449160-07-0P 449160-95-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of oxazole derivs. and their use as cytokine inhibitors)
RN 449159-60-8 CAPLUS
CN 4-Oxazolecarboxamide, 5-[4-(dimethylamino)phenyl]-2-[4-(1,1-dimethylethyl)phenyl]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 449160-07-0 CAPLUS
CN 4-Oxazolecarboxamide, 5-[4-(acetylamino)phenyl]-2-[4-(1,1-dimethylethyl)phenyl]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 449160-95-6 CAPLUS
CN 4-Oxazolecarboxamide, 5-[3-(dimethylamino)phenyl]-2-[4-(1,1-dimethylethyl)phenyl]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)


t-Bu
Me2N
O
N
C=O
NH

L4 ANSWER 4 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 2002:554265 CAPLUS
DN 137:243205
TI Comparison of the computer programs DEREK and TOPKAT to predict bacterial mutagenicity
AU Cariello, Neal F.; Wilson, John D.; Britt, Ben H.; Wedd, David J.; Burlinson, Brian; Gombar, Vijay
CS Safety Assessment, GlaxoSmithKline Inc., Research Triangle Park, NC, 27709, USA
SO Mutagenesis (2002), 17(4), 321-329
CODEN: MUTAEX; ISSN: 0267-8357
PB Oxford University Press
DT Journal
LA English
AB The performance of two computer programs, DEREK and TOPKAT, was examd. with regard to predicting the outcome of the Ames bacterial mutagenicity assay. The results of over 400 Ames tests conducted at Glaxo Wellcome (now GlaxoSmithKline) during the last 15 yr on a wide variety of chem. classes were compared with the mutagenicity predictions of both computer programs. DEREK was considered concordant with the Ames assay if (i) the Ames assay was neg. (not mutagenic) and no structural alerts for mutagenicity were identified or (ii) the Ames assay was pos. (mutagenic) and at least one structural alert was identified. Conversely, the DEREK output was considered discordant if (i) the Ames assay was neg. and any structural alert was identified or (ii) the Ames assay was pos. and no structural alert was identified. The overall concordance of the DEREK program with the Ames results was 65% and the overall discordance was 35%, based on over 400 compds. About 23% of the test mols. were outside the permissible limits of the optimum prediction space of TOPKAT. Another 4% of the compds. were either not processable or had indeterminate mutagenicity predictions; these mols. were excluded from the TOPKAT anal. If the TOPKAT probability was (i) .gtoreq.0.7 the mol. was predicted to be mutagenic, (ii) .ltoreq.0.3 the compd. was predicted to be non-mutagenic and (iii) between 0.3 and 0.7 the prediction was considered indeterminate. From over 300 acceptable predictions, the overall TOPKAT concordance was 73% and the overall discordance was 27%. While the overall concordance of the TOPKAT program was higher than DEREK, TOPKAT fared more poorly than DEREK in the crit. Ames-pos. category, where 60% of the compds. were incorrectly predicted by TOPKAT as neg. but were mutagenic in the Ames test. For DEREK, 54% of the Ames-pos. mols. had no structural alerts and were predicted to be non-mutagenic. Alternative methods of analyzing the output of the programs to increase the accuracy with Ames-pos. compds. are discussed.
IT **461053-64-5**
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(computer programs DEREK and TOPKAT to predict bacterial mutagenicity)
RN 461053-64-5 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)benzoyl]-N-[(1S)-1,2,3,4-tetrahydro-7-methyl-1-naphthalenyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 2002:539670 CAPLUS
DN 137:93746
TI 2-Arylimino-2,3-dihydrothiazoles, processes for their preparation, and their use as somatostatin receptor ligands
IN Moinet, Christophe; Sackur, Carole; Thurieau, Christophe
PA Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.), Fr.
SO PCT Int. Appl., 465 pp.
CODEN: PIXXD2
DT Patent
LA French

not prior

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002055510	A1	20020718	WO 2002-FR93	20020111
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	FR 2819508	A1	20020719	FR 2001-396	20010112
PRAI	FR 2001-396	A	20010112		

OS MARPAT 137:93746

AB The invention concerns novel 2-arylimino-2,3-dihydrothiazole derivs. I and their racemates, enantiomers, combinations, and salts [wherein R1 = (un)substituted, particularly amino-substituted alk(en/yn)yl, (hetero)aryl, aralkyl, cycloalkyl, etc.; R2 = (un)substituted carbocyclic or heterocyclic aryl; R3 = alkyl, adamantyl, (un)substituted (hetero)aryl or (hetero)aralkyl, (un)substituted carbamoyl; R4 = H, alkyl, (un)substituted (hetero)aralkyl, etc.]. Also disclosed are methods of their prepn. and their use as medicines, in particular for treating a wide variety of pathol. conditions or diseases involving somatostatin receptors. In particular, these pathol. conditions include acromegaly, pituitary adenoma, endocrine gastroenteropancreatic tumors (including carcinoid syndrome), and gastrointestinal bleeding. Examples include a few detailed syntheses, a listing of over 2800 characterized invention compds., and various precursor prepns. For instance, 4-H2NC6H4CH2CH2NH2 was bound to Wang resin p-nitrophenylcarbonate (at the aliph. amino group), and the resin-bound amine reacted sequentially with PhCH2CH2NCS, bromopyruvic acid, and 4-ClC6H4CH2NH2 to give, after acidic cleavage, (Z)-isomeric title compd. II. Twenty selected compds. I, including III.2HCl, inhibited binding of [125I-Tyr11]SRIF-14 to human somatostatin receptors in vitro with Ki < 200 nM.

IT **322747-60-4P 322747-74-0P 322747-88-6P**
322748-02-7P 322748-30-1P 322748-50-5P
322748-70-9P 322748-90-3P 322750-11-8P
322750-27-6P 322750-43-6P 322750-59-4P
322750-75-4P
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of (arylimino)dihydrothiazoles as somatostatin

receptor ligands)

RN 322747-60-4 CAPLUS

CN 4-Thiazolecarboxamide, 3-(6-aminohexyl)-2,3-dihydro-2-[(3-nitrophenyl)imino]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 322747-74-0 CAPLUS

CN 4-Thiazolecarboxamide, 3-(6-aminohexyl)-2,3-dihydro-2-[(4-phenoxyphenyl)imino]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 322747-88-6 CAPLUS

CN 4-Thiazolecarboxamide, 3-(6-aminohexyl)-2,3-dihydro-2-[[4-(1-piperidinylsulfonyl)phenyl]imino]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)-

(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 322748-02-7 CAPLUS
CN 4-Thiazolecarboxamide, 3-(6-aminohexyl)-2-[(3-bromophenyl)imino]-2,3-dihydro-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 322748-30-1 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-2-[(3,5-dimethylphenyl)imino]-2,3-dihydro-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 322748-50-5 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-2,3-dihydro-2-(1-naphthalenylimino)-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 322748-70-9 CAPLUS
CN 4-Thiazolecarboxamide, 3-(5-aminopentyl)-2-[(3,5-dimethylphenyl)imino]-2,3-dihydro-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 322748-90-3 CAPLUS
CN 4-Thiazolecarboxamide, 3-(5-aminopentyl)-2,3-dihydro-2-(1-naphthalenylimino)-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 322750-11-8 CAPLUS
CN 4-Thiazolecarboxamide, 2-[[3-(aminomethyl)phenyl]imino]-2,3-dihydro-3-(2-phenylethyl)-N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 322750-27-6 CAPLUS
CN 4-Thiazolecarboxamide, 2-[[3-(aminomethyl)phenyl]imino]-2,3-dihydro-3-(2-methylpropyl)-N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 322750-43-6 CAPLUS
CN 4-Thiazolecarboxamide, 2-[[3-(aminomethyl)phenyl]imino]-2,3-dihydro-3-(1-naphthalenylmethyl)-N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 322750-59-4 CAPLUS

CN 4-Thiazolecarboxamide, 2-[[3-(aminomethyl)phenyl]imino]-3-[(4-chlorophenyl)methyl]-2,3-dihydro-N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 322750-75-4 CAPLUS
CN 4-Thiazolecarboxamide, 2-[[3-(aminomethyl)phenyl]imino]-2,3-dihydro-3-[(2-methoxyphenyl)methyl]-N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 2002:521709 CAPLUS
DN 137:93689
TI Preparation of pyridone derivatives having affinity for cannabinoid type 2 receptor
IN Tada, Yukio; Iso, Yasuyoshi; Hanasaki, Kohji
PA Shionogi & Co., Ltd., Japan
SO PCT Int. Appl., 307 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002053543	A1	20020711	WO 2001-JP11427	20011226

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI JP 2000-400768 A 20001228
OS MARPAT 137:93689
AB The title compds. I [R1 represents a group represented by the formula Y1Y2Y3Ra (wherein Y1 is a single bond, etc.; Y2 is C(:O)NH, etc.; and Y3 is optionally substituted aryl, etc.; Ra is (un)substituted alkyl, etc.), etc.; R2 represents hydrogen, etc.; R3 represents alkyl, etc.; R4 represents alkyl, etc.; and R5 represents optionally substituted alkyl, etc.; X is S or O; a proviso is given] are prepd. In an in vitro test for human CB2 receptor binding inhibition, compds. of this invention showed the Ki values of 1.5 nM to 101 nM. In an in vitro test for human CB1 receptor binding inhibition, compds. of this invention showed the Ki values of 54 nM to > 5000 nM.
IT **441303-36-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyridone derivs. having affinity for cannabinoid type 2 receptor)
RN 441303-36-2 CAPLUS
CN 3-Pyridinecarboxamide, 1-(cyclohexylmethyl)-1,2-dihydro-5,6-dimethyl-2-oxo-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 2002:293652 CAPLUS
DN 136:325531
TI Preparation of (poly)azanaphthalenyl carboxamides as HIV integrase inhibitors
IN Anthony, Neville J.; Gomez, Robert P.; Young, Steven D.; Egbertson, Melissa; Wai, John S.; Zhuang, Linghang; Embrey, Mark; Tran, Lekhanh; Melamed, Jeffrey Y.; Langford, H. Marie; Guare, James P.; Fisher, Thorsten E.; Jolly, Samson M.; Kuo, Michelle S.; Perlow, Debra S.; Bennett, Jennifer J.; Funk, Timothy W.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 434 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002030930	A2	20020418	WO 2001-US31456	20011009
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002011527	A5	20020422	AU 2002-11527	20011009
PRAI	US 2000-239707P	P	20001012		
	US 2001-281656P	P	20010405		
	WO 2001-US31456	W	20011009		

OS MARPAT 136:325531
AB Title compds., including certain quinoline carboxamide and naphthyridine carboxamide derivs., I [wherein A = (un)substituted Ph or Ph fused to a carbocycle; L = a single bond, or (un)substituted alkyl, alkenyl, alkylcycloalkylalkyl, or alkyl-M-alkyl; M = NRa, OCO, or CO2; X = N or CQ1; Y = N or CQ2, provided that X and Y are not both N; Z1 = N or CQ3; Z2 = N or CQ4; Z3 = N or CH; Q1-Q4 = independently H, halo, CN, NR1CR1O, or (un)substituted alkyl, alkoxy, alkenyl, alkynyl, carbamoyl, carboximidamido, amino, etc.; or C2Q2Q3 = (un)substituted 5- or 6-membered carbocycle or heterocycle; R1 and R2 = independently H, OH, halo, NO2, CN, or (un)substituted alkyl, alkenyl, alkoxy, amino, sulfonylamino, etc.; R3 and R4 = independently H, halo, CN, NO2, OH, alkenyl, or (un)substituted alkyl, amino, sulfonylamino, etc.; R5 = H, CN, CN, or (un)substituted alkyl or aryl; Ra = independently H or (halo)alkyl; or pharmaceutically acceptable salts thereof] were prepd. I are inhibitors of HIV integrase and inhibitors of HIV replication, and are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, as compds. or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compns., optionally in combination with other antivirals, immunomodulators, antibiotics, or vaccines. For example, Mitsunobu reaction of iso-Pr 3-(hydroxymethyl)pyridine-2-carboxylate with Me N-[(4-methylphenyl)sulfonyl]glycinate, followed by cyclization in the presence on NaOMe, afforded Me 8-hydroxy-1,6-naphthyridine-7-carboxylate. Coupling with 3,5-dichlorobenzylamine in toluene gave II. Representative compds. were assayed for the inhibition of acute HIV infection of T-lymphoid cells and demonstrated IC95 values of < 20 .mu.M.

IT **410543-06-5P**, 8-Hydroxy-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,6-naphthyridine-7-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(HIV integrase inhibitor; prepn. of (poly)azanaphthalenyl carboxamides as HIV integrase inhibitors for treatment of AIDS)

RN 410543-06-5 CAPLUS

CN 1,6-Naphthyridine-7-carboxamide, 8-hydroxy-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 8 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 2002:185126 CAPLUS
DN 136:247485
TI Preparation of bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors
IN Bartlett, Julie B.; Freeman, Sue; Kenny, Peter; Morley, Andrew; Whittamore, Paul
PA Astrazeneca AB, Swed.
SO PCT Int. Appl., 141 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002020530	A1	20020314	WO 2001-SE1880	20010831
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001082833	A5	20020322	AU 2001-82833	20010831
PRAI GB 2000-21831	A	20000906		
WO 2001-SE1880	W	20010831		

OS MARPAT 136:247485
AB Title compds. I [R1 = H, halo, NO2, CN , OH, (un)substituted alkyl, alkenyl, etc.; R2 = H, halo, NO2, CH2F, CHF2, CF3, amino, alkyl, alkenyl, alkoxy, etc.; R3 = H, alkyl; -X-Y-Z- is selected from -S-CR4=CR5-, -CR4=CR5-S-, -O-CR4=CR5-, -CR4=CR5-O-, -N=CR4-S-, -S-CR4=N-, -NR3-CR4=CR5- and -CR4=CR5-NR3- wherein R4 and R5 = independently H, halo, CN, alkyl, ureido, NO2, etc.; n = 0-4] or a pharmaceutically acceptable salt or an in vivo hydrolyzable ester thereof were prepd. possessing glycogen phosphorylase inhibitory activity (no data). Thus, II was prepd. by amidation of 5-carboxy-2,3-dichloro-4H-thieno[3,2-b]pyrrole with 2-phenoxyethylamine. As glycogen phosphorylase inhibitors, I have value in the treatment of disease states assocd. with increased glycogen phosphorylase activity, e.g., type 2 diabetes. Pharmaceutical compns. contg. I are described.
IT **403859-27-8P 403859-87-0P 403859-89-2P**
403860-71-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compd.; prepn. of thienopyrrolyl amides as glycogen phosphorylase inhibitors)
RN 403859-27-8 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-(1,2,3,4-tetrahydro-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 403859-87-0 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-1,2,3,4-tetrahydro-1-hydroxy-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 403859-89-2 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-(1,2,3,4-tetrahydro-7-methoxy-1-oxo-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 403860-71-9 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-(1,2,3,4-tetrahydro-1-hydroxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 2002:171898 CAPLUS
DN 136:232298
TI Pyrazolopyridine compounds and pharmaceutical use thereof as adenosine receptor antagonists
IN Akahane, Atsushi; Tanaka, Akira; Minagawa, Masatoshi; Itani, Hiromichi; Ohtake, Hiroaki
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 149 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002018382	A1	20020307	WO 2001-JP7322	20010827
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001080188	A5	20020313	AU 2001-80188	20010827
PRAI	AU 2000-9698	A	20000828		
	WO 2001-JP7322	W	20010827		

OS MARPAT 136:232298
AB Pyrazolopyridines I are disclosed [wherein: R1 = H, (un)substituted lower alkyl or cycloalkyl which may be interrupted by an O or N; R2 = H, halo, or lower alkoxy; R3 = independent substituent(s); and n = 1 to 4; or a salt thereof]. The compds. are adenosine antagonists, and are thus useful for the prevention and/or treatment of a wide variety of medical conditions, e.g., depression, dementia (e.g., Alzheimer's disease, cerebrovascular dementia, dementia accompanying Parkinson's disease, etc.) Parkinson's disease, anxiety, pain, cerebrovascular disease (e.g. stroke, etc.), heart failure, and the like. In particular, treatment of Parkinson's disease and/or assocd. symptoms is specifically claimed. Over 330 example compds. are described. For instance, cyclization of 1-amino-4-methoxypyridinium iodide with 3-(benzenesulfonyl)-6-(phenylethynyl)pyridazine, gave 3-(3-phenylsulfonylpyridazin-6-yl)-5-methoxy-2-phenylpyrazolo[1,5-a]pyridine. This compd. was hydrolyzed at the phenylsulfinyl group, and the resultant pyridazinone was N-alkylated with NaH/DMF and iso-PrI to give title compd. II. In radioligand binding assays, II had Ki values of 0.15 nM for human A1 receptors and 1.38 nM for human A2A receptors. In an anticatalepsy test in mice, 6 tested example compds. I at 3.2 mg/kg orally completely suppressed the cataleptic effects of haloperidol at 0.32 mg/kg i.p.
IT **403495-70-5P**, N-(1,2,3,4-Tetrahydronaphthalen-1-yl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of pyrazolopyridines as adenosine receptor antagonists)
RN 403495-70-5 CAPLUS

CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 2002:171866 CAPLUS
DN 136:232313
TI Preparation of pyrimidine derivatives as G protein-coupled receptor kinase (GRK) inhibitors
IN Fukumoto, Shoji; Watanabe, Toshifumi; Ikeda, Shota
PA Takeda Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 322 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002018350	A1	20020307	WO 2001-JP7397	20010829
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001082520	A5	20020313	AU 2001-82520	20010829
	JP 2002145778	A2	20020522	JP 2001-259683	20010829
PRAI	JP 2000-264499	A	20000829		
	WO 2001-JP7397	W	20010829		

OS MARPAT 136:232313
AB Disclosed are novel GRK inhibitors which contains compds. represented by the formula (I), a salt thereof, or a prodrug comprising either of these (wherein ring A represents optionally further substituted nitrogen-contg. heterocycle; R1 and R2 each represents optionally substituted amino; and X represents a spacer comprising a linear part constituted of one to four atoms, provided that R1 may be bonded to R2 or/and X to form a ring). They are useful as preventives/remedies for cardiac failure. Thus, 5.48 g K2CO3 and 7.52 g 2-aminophenyl 2-nitrophenyl sulfide were added to a suspension of 5.61 g 4-amino-5-bromomethyl-2-methylpyrimidine hydrobromide in 40 mL acetone at room temp. and stirred at 65.degree. for 64 h to give 2.36 g N-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-N-[2-[(2-nitrophenyl)thio]phenyl]amine (II). All 10 compds. tested including II at 30 .mu.M inhibited 30% human GRK2 expressed by human GRK2 gene in COS-7 cells. A capsule and a tablet formulation contg. II were also prepd.
IT **403514-90-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrimidine derivs. as G protein-coupled receptor kinase (GRK) inhibitors for prevention and/or treatment for cardiac failure)
RN 403514-90-9 CAPLUS
CN 1H-Isoindole-5-carboxamide, 2-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-2,3-dihydro-1,3-dioxo-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 2002:31456 CAPLUS
DN 136:85755
TI Preparation of thieno[2,3-b]pyrrolidin-5-ones as inhibitors of cellular prodn. of tumor necrosis factor (TNF-.alpha.) and as antiproliferative agents
IN Gill, Adrian Liam; Harris, William
PA F. Hoffmann-La Roche A.-G., Switz.
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002002567	A1	20020110	WO 2001-EP7423	20010628
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002028841	A1	20020307	US 2001-891588	20010626
	US 6528653	B2	20030304		
PRAI	GB 2000-16454	A	20000704		

OS MARPAT 136:85755
AB The title compds. [I; R1 = (un)substituted 5-6 membered monocyclic arom. ring contg. one or more heteroatoms selected from N, S, and O, the remaining being C atom, and which ring may be benz-fused; R2 = H; R3 = H, CN, halo, etc.], useful in the treatment of neuro-degenerative diseases, cardiovascular diseases, cancer or inflammatory diseases, were prepd. and formulated. Thus, reacting 4,6-dihydrothieno[2,3-b]pyrrol-5-one (prepn. given) with pyrrole-2-carboxaldehyde in a soln. of 1% piperidine in 2-propanol afforded (Z)-I [R1 = 1H-pyrrol-2-yl; R2, R3 = H] which showed IC50 of 5.08 .mu.M against human TNF-.alpha. biosynthesis.
IT **387390-22-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of thieno[2,3-b]pyrrolidin-5-ones as inhibitors of cellular prodn. of tumor necrosis factor (TNF-.alpha.) and as antiproliferative agents)
RN 387390-22-9 CAPLUS
CN 4H-Thieno[2,3-b]pyrrole-2-carboxamide, 5,6-dihydro-5-oxo-4-(1H-pyrrol-2-ylmethylene)-N-(1,2,3,4-tetrahydro-1-naphthalenyl)-, (4Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 2001:597958 CAPLUS
DN 135:166827
TI Preparation of 1H-indole-3-carboxamides, 1H-indazole-3-carboxamides, 1H-pyrido[4,3-b]indol-1-ones and pyrrolo[1,2,3-de]-1,4-benzoxazine-6-carboxamides as cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
IN Leftheris, Katerina; Zhao, Rulin; Chen, Bang-Chi; Kiener, Peter; Wu, Hong; Pandit, Chennagiri R.; Wrobleski, Stephen; Chen, Ping; Hynes, John, Jr.; Longphre, Malinda; Norris, Derek J.; Spergel, Steven; Tokarski, John
PA Bristol-Myers Squibb Company, USA; et al.
SO PCT Int. Appl., 199 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001058869	A2	20010816	WO 2001-US4131	20010208
	WO 2001058869	A3	20020124		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002119972	A1	20020829	US 2001-779109	20010208
	EP 1254115	A2	20021106	EP 2001-907144	20010208
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	US 2000-181818P	P	20000211		
	WO 2001-US4131	W	20010208		

OS MARPAT 135:166827
AB The title compds. [I; A, B = C, N so that ring X = pyrrole, pyrazole or imidazole (wherein when A = N, the group CONR1R2 is attached to atom C-3 and R5 does not exist; and when A = C, one of CONR1R2 and R5 is attached to A and the other to atom C-3; and when B = C, two R4 groups attached to B and atom C-5, resp., form a fused 6-membered hetroaryl); f = 0-1; g = 1-2; R1, R2 = H, alkyl, heterocycloalkyl, etc.; R2 together with R1 or R5 forms a 5-6 membered heterocyclo; R3 = H, alkyl, aryl, etc.; R4 is attached to atom C-5 and optionally B and is H, alkyl, aryl, etc.; R5 is attached to A or atom C-3 and is H, alkyl, aryl, etc.; R5 together with R2 forms a heterocyclo], useful as cannabinoid receptor modulators (no data given) for treating respiratory and non-respiratory leukocyte-activation assocd. diseases, were prepd. Thus, reacting the acid chloride II [X = Cl] (multi-step synthesis given) with 2,2,6,6-tetramethylcyclohexylamine afforded the pyrrolo[1,2,3-de]-1,4-benzoxazine-6-carboxamide II [X = 2,2,6,6-tetramethylcyclohexylamino].
IT **354570-87-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 1H-indole-3-carboxamides, 1H-indazole-3-carboxamides, 1H-pyrido[4,3-b]indol-1-ones and pyrrolo[1,2,3-de]-1,4-benzoxazine-6-carboxamides as cannabinoid receptor modulators for treating

respiratory and non-respiratory diseases)

RN 354570-87-9 CAPLUS

CN 1H-Indazole-3-carboxamide, 7-methoxy-1-[2-(4-morpholinyl)ethyl]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 13 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 2001:416942 CAPLUS
DN 135:19660
TI Preparation of pyrazolo[1,5-a]pyrimidines as potassium channel inhibitors
IN Atwal, Karnail S.; Vaccaro, Wayne; Lloyd, John; Finlay, Heather; Yan, Lin; Bhandaru, Rao S.
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 298 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001040231	A1	20010607	WO 2000-US32785	20001204
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1237891	A1	20020911	EP 2000-980930	20001204
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	US 2003022890	A1	20030130	US 2000-729731	20001205
	NO 2002002649	A	20020606	NO 2002-2649	20020605
PRAI	US 1999-169091P	P	19991206		
	US 2000-236037P	P	20000928		
	WO 2000-US32785	W	20001204		

OS MARPAT 135:19660
AB The title compds. [I; X1-X3 = N, NR6, (CR7)q, (CHR7)q, CO; R1-R7 = (CH2)n(Z1)m(CH2)pZ2; or R1-R5 may, in one or more pairs of two, together with the atoms to which they are bonded, form (un)substituted carbocyclic, heterocyclic group; or R6 and R7 may, together with the atoms to which they are bonded, form (un)substituted carbocyclic, heterocyclic group; Z1 = O, S, CO, etc.; Z2 = H, NO2, halo, etc.; n, p = 0-10 (when m = 0, p is also 0); m = 0-1; q = 1-3], useful as inhibitors of potassium channel function (esp. inhibitors of the Kv1 subfamily of voltage gated K+ channels, esp. inhibitors Kv1.5 which has been linked to the ultra-rapidly activating delayed rectifier K+ current IKur) in the prevention and treatment of arrhythmia and IKur-assocd. conditions, were prepd. Thus, reacting Me acetoacetate with 2,3-dichlorobenzaldehyde in the presence of piperidine and AcOH in PhMe followed by refluxing the resulting intermediate II with 3-aminopyrazole in 1-propanol afforded the title compd. III. The compds. I are effective at 0.001-100 mg/kg/day.
IT **343244-41-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrazolo[1,5-a]pyrimidines as potassium channel inhibitors)
RN 343244-41-7 CAPLUS
CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, 7-(3,4-dichlorophenyl)-4,7-dihydro-5-methyl-N-(1,2,3,4-tetrahydro-1-naphthalenyl)-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 23 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 2000:314676 CAPLUS
DN 132:334362
TI Preparation of picolinamide derivatives and pest controllers containing the same as the active ingredient
IN Imamura, Keiichi; Mitomo, Kouichi; Yamada, Natsuko; Yamamoto, Kazumi; Teraoka, Takeshi; Sakanaka, Osamu; Kurihara, Hiroshi; Taniguchi, Makoto
PA Meiji Seika Kaisha, Ltd., Japan
SO PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000026191	A1	20000511	WO 1999-JP6142	19991104
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1134214	A1	20010919	EP 1999-954375	19991104
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	JP 1998-313688	A	19981104		
	WO 1999-JP6142	W	19991104		

OS MARPAT 132:334362
AB Described are novel compds. of general formula [I; wherein A is a bond or optionally substituted alkylene; R1 is one or more groups which may be the same or different from each other and are selected from among hydrogen, alkoxy and haloalkoxy; R2 is hydrogen, (substituted) benzyl, (substituted) alkyl or (substituted) alkanoyl; and R3 is hydrogen, (substituted) cycloalkyl, (substituted) cycloalkenyl, (substituted) aryl, or a (substituted) heterocyclic group, with the proviso that the cases wherein R1 is hydrogen, A is a free valency or methylene, and R3 is Ph or cyclohexyl or those wherein A is alkylene and R3 is hydrogen are excepted.], pest controllers such as plant fungicides, insecticides, and herbicides contg. the same; and a process for the prepn. of the compds. Thus, a soln. of 1.85 g 4-phenoxyaniline in 25 mL DMF was added dropwise to a suspension of 1.39 g 3-hydroxypicolinic acid, 1.95 g carbonyl diimidazole, and 30 mL DMF and stirred overnight to give 41% 3-hydroxy-4'-phenoxypicolinanilide (II). II at 100 ppm protected 80-100% rice seedlings against Pyricularia oryzae.
IT **267416-15-9P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of picolinamide derivs. as pest controllers)
RN 267416-15-9 CAPLUS
CN 2-Pyridinecarboxamide, 3-hydroxy-4-methoxy-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 24 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 2000:241135 CAPLUS
DN 132:279106
TI Non-peptide GnRH agents, methods and intermediates for their preparation
IN Anderson, Mark Brian; Vazir, Haresh N.; Luthin, David Robert; Paderes, Genevieve Deguzman; Pathak, Ved P.; Christie, Lance Christopher; Hong, Yufeng; Tompkins, Eileen Valenzuela; Li, Haitao; Faust, James
PA Agouron Pharmaceuticals, Inc., USA; et al.
SO PCT Int. Appl., 444 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000020358	A2	20000413	WO 1999-US18790	19990820
	WO 2000020358	A3	20001116		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2341346	AA	20000413	CA 1999-2341346	19990820
	BR 9913374	A	20010515	BR 1999-13374	19990820
	EP 1105120	A2	20010613	EP 1999-968010	19990820
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	EE 200100102	A	20020617	EE 2001-200100102	19990820
	JP 2002535244	T2	20021022	JP 2000-574479	19990820
	NO 2001000309	A	20010411	NO 2001-309	20010119
	LV 12732	B	20020320	LV 2001-45	20010316
	LT 4904	B	20020425	LT 2001-24	20010319
PRAI	US 1998-97520P	P	19980820		
	WO 1999-US18790	W	19990820		

OS MARPAT 132:279106
AB Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. The compds. and their pharmaceutically acceptable salts, multimers, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. The compds. include those of formula I [X = C:O, C:S, S:O, or SO2; Het = 5-membered NOS-heterocycle; R1, R2 = H, alkyl; R3-R7 = H, halo, (un)substituted alkyl, aryl, heteroaryl, CH2OR, OR, CO2R; R = alkyl, aryl, etc.; adjacent rings positions such as R6R7 may form (un)substituted 5- or 6-membered ring with up to 4 heteroatoms; R8 = lipophilic moiety such as alkyl, aryl, CH2OR, OR, etc.; R9 = H, (un)substituted alkyl]. Methods and intermediates for synthesizing the compds. are also described. For instance, 4,4,7-trimethylchroman (prepn. given) was alkylated in the 6- and 8-positions using Et 5-(chloromethyl)-2-furoate (46% total yield), and the resulting esters were hydrolyzed to a mixt. of acids. This unsepd. mixt. was treated with SOCl2 and amidated with 2,4,6-trimethoxyphenylamine-HCl to give the invention compd. II and its chroman-6-position isomer, which were sepd. by HPLC. Several compds. exhibited high affinity (<100

nM) at human GnRH receptors. The compds. antagonized GnRH-stimulated inositol phosphate accumulation in cells with recombinant human GnRH receptors, and an example compd. reduced plasma LH levels in castrated male rats. Various biol. data for several hundred compds. are given.

IT **263855-10-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compd.; prepn. of non-peptide GnRH agents for regulating gonadotropin secretion)

RN 263855-10-3 CAPLUS

CN 2-Furancarboxamide, N-(1,2,3,4-tetrahydro-1-naphthalenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 27 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 1999:511160 CAPLUS
DN 131:144604
TI Preparation of oxodipyridoimidazole-carboxamides: GABAa brain receptor ligands
IN Xie, Linghong; Currie, Kevin S.; Albaugh, Pamela; Shaw, Kenneth; Hutchison, Alan J.
PA Neurogen Corporation, USA
SO PCT Int. Appl., 186 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9940092	A1	19990812	WO 1999-US1688	19990204
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9926534	A1	19990823	AU 1999-26534	19990204
PRAI US 1998-18754		19980204		
WO 1999-US1688		19990204		

OS MARPAT 131:144604
AB Title compds. [I; A represents an optionally substituted nitrogen-contg. ring system; R is H, alkyl cycloalkyl, arylalkyl, heteroarylalkyl; G, an org. or inorg. group, is cycloalkyl, alkyl, etc.], stereoisomers, and pharmaceutically acceptable salts thereof are prepd. and are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors, and are therefore useful in the diagnosis and treatment of anxiety, Down Syndrome, sleep, cognitive and seizure disorders, depression, overdose with benzodiazepine drugs and for enhancement of alertness. Thus, the title compd. II, tested on rat cortical tissue, was prepd. from redn., cyclizaion of 4-chloro-3-nitropyridine, Et 3-aminopropionate, Et 3-amino-3-ethoxyacrylate hydrochloride, 2-fluorobenzylamine, and methylation by Me iodide.
IT **235769-48-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of oxodipyridoimidazolylcarboxamides on GABAa receptor activities)
RN 235769-48-9 CAPLUS
CN Dipyrido[1,2-a:3',4'-d]imidazole-9-carboxamide, 6,7,8,10-tetrahydro-8-oxo-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 30 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 1999:390374 CAPLUS
DN 131:44810
TI Preparation of naphthyridines and thiazolopyridines as antiviral agents
IN Bedard, Jean; Rando, Robert; Lavallee, Jean-Francois; Falardeau, Guy
PA Biochem Pharma Inc., Can.
SO PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9929318	A1	19990617	WO 1998-CA1166	19981211
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2314408	AA	19990617	CA 1998-2314408	19981211
	AU 9916579	A1	19990628	AU 1999-16579	19981211
	AU 740745	B2	20011115		
	EP 1037633	A1	20000927	EP 1998-960978	19981211
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9815166	A	20001010	BR 1998-15166	19981211
	US 6255318	B1	20010703	US 1998-209485	19981211
	JP 2001525365	T2	20011211	JP 2000-523989	19981211
	US 2001031765	A1	20011018	US 2001-775571	20010205
PRAI	US 1997-69331P	P	19971211		
	US 1998-209485	A3	19981211		
	WO 1998-CA1166	W	19981211		

AB The title compds. I [W = CH, CR3, CH2, CO, N, etc.; one of X, Y, and Z is N or NR5 while the other two are CH, CR4, CH2, CO, CHR4; Q = CH, CR3, CH2, CO, CHR3, N, NR5, O; B = C(A)NR1R2, NR2'C(A)R1, NR2'C(A)NR1R2 and A = O, N, S], antiviral agents, were prepd. E.g., N-(2-methylbenzyl)-2-[1,6]naphthyridinecarboxamide was prepd. Among the antiviral activities were those detd. with HSV-1, HSV-2, influenza B, adenovirus, and HIVROJO.

IT **197506-74-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of naphthyridines and thiazolopyridines as antiviral agents)

RN 197506-74-4 CAPLUS
CN 1,6-Naphthyridine-2-carboxamide, N-(1,2,3,4-tetrahydro-1-naphthalenyl)-(9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 36 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 1997:640666 CAPLUS
DN 127:318884
TI Preparation of naphthyridines inhibiting cytomegalovirus
IN Jin, Haolun; Chan, Laval Chun-Kong; Wang, Wei; Stefanac, Tomislav; Mansour, Tarek S.; Nguyen-Ba, Paul; Lavallee, Jean-Francois; Falardeau, Guy
PA Biochem Pharma Inc., Can.; Jin, Haolun; Chan, Laval Chun-Kong; Wang, Wei; Stefanac, Tomislav; Mansour, Tarek S.; Nguyen-Ba, Paul; Lavallee, Jean-Francois; Falardeau, Guy
SO PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9734894	A1	19970925	WO 1997-CA182	19970314
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2250320	AA	19970925	CA 1997-2250320	19970314
	AU 9719187	A1	19971010	AU 1997-19187	19970314
	AU 722650	B2	20000810		
	GB 2326412	A1	19981223	GB 1998-19782	19970314
	CN 1218473	A	19990602	CN 1997-194535	19970314
	CN 1069643	B	20010815		
	BR 9708068	A	20000104	BR 1997-8068	19970314
	EP 984967	A1	20000315	EP 1997-906955	19970314
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2001515464	T2	20010918	JP 1997-532997	19970314
	ZA 9702292	A	19971016	ZA 1997-2292	19970317
	TW 480258	B	20020321	TW 1997-86103467	19970319
	US 5945431	A	19990831	US 1997-923604	19970904
PRAI	GB 1996-5437	A	19960315		
	WO 1997-CA182	W	19970314		

OS MARPAT 127:318884
AB The title compds. [I; W = CH, CH2, C(O), etc.; one of X, Y, Z = N, NR5 while the other two are CH, CR4, CH2, C(O), CHR4; B = C(O)NR1R2, C(S)NR1R2, NR2aC(A)NR2R1; A = O, S; R1 = C1-6 alkyl, C2-6 alkenyl, C3-7 cycloalkyl, etc.; R2, R2a = H, C1-4 alkyl; R1R2 = (un)satd. 5-6 membered heterocycle optionally fused to C6-10 aryl or heteroaryl; R3, R4 = H, OH, halo, etc.; n = 0-2], useful in the therapy and prophylaxis of cytomegalovirus (CMV) infection in mammals, were prepd. Thus, treatment of 2-[1,6]naphthridinecarboxylic acid with iso-Pr chloroformate/PhMe in the presence of Et3N in THF followed by addn. of 2-methylbenzylamine afforded 37% II which showed IC50 of .apprxeq. 1 .mu.g/mL against CMV.
IT **197506-74-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of naphthyridines inhibiting cytomegalovirus)

RN 197506-74-4 CAPLUS
CN 1,6-Naphthyridine-2-carboxamide, N-(1,2,3,4-tetrahydro-1-naphthalenyl)-
(9CI) (CA INDEX NAME)



L4 ANSWER 41 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 1996:560560 CAPLUS
DN 125:195662
TI Preparation of herbicidal [1,2,4]thiadiazolecarboxamides
PA American Cyanamid Company, USA
SO Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 726260	A1	19960814	EP 1995-101693	19950208
	R: DE				
	US 5583092	A	19961210	US 1995-441565	19950515
	JP 08259551	A2	19961008	JP 1996-40292	19960205
	CA 2168926	AA	19960809	CA 1996-2168926	19960206
	EP 726261	A1	19960814	EP 1996-300801	19960206
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	AU 9644406	A1	19960815	AU 1996-44406	19960207
	ZA 9600977	A	19970807	ZA 1996-977	19960207
	BR 9600342	A	19980127	BR 1996-342	19960207
	CN 1134936	A	19961106	CN 1996-103589	19960208
PRAI	EP 1995-101693	A	19950208		

OS CASREACT 125:195662; MARPAT 125:195662
AB The title compds. [I and II; A = (substituted) alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, aralkyl or heteroaralkyl; R1 = H, acyl; R2 = (substituted) alkyl, alkenyl, aryl, heteroaryl, aralkyl or heteroaralkyl] were prepd. Thus, reaction of isobutyramide with chlorocarbonylsulphenyl chloride followed by treatment of 5-isopropyl-[1,3,4]thiazolin-2-one with Et cyanoformate in p-xylene and reaction of Et 3-isopropyl-[1,2,4]thiadiazole-5-carboxylate with 1-(thiophen-2-yl)ethylamine in PhMe afforded II [A = iPr; R1 = H; R2 = 2-thienyl-CH(Me)] which showed 100% herbicidal activity against Beta vulgaris, Linum usitatissimum, Echinochloa crus-galli and Synapsis alba in postemergence tests.
IT **180970-42-7P 180970-43-8P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of herbicidal [1,2,4]thiadiazolecarboxamides)
RN 180970-42-7 CAPLUS
CN 1,2,4-Thiadiazole-5-carboxamide, 3-(2-fluorophenyl)-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 180970-43-8 CAPLUS
CN 1,2,4-Thiadiazole-5-carboxamide, 3-(4-methoxyphenyl)-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 43 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 1995:605693 CAPLUS
DN 123:9446
TI Preparation of herbicidal 1,2,4-oxadiazolecarboxamides.
IN Buck, Wolfgang
PA Shell Internationale Research Maatschappij B. V., Neth.
SO Eur. Pat. Appl., 45 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 647635	A1	19950412	EP 1994-307357	19941006
	EP 647635	B1	19980708		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	US 5578550	A	19961126	US 1994-318327	19941005
	CA 2133798	AA	19950409	CA 1994-2133798	19941006
	AT 168108	E	19980715	AT 1994-307357	19941006
	ES 2120576	T3	19981101	ES 1994-307357	19941006
	AU 9474488	A1	19950427	AU 1994-74488	19941007
	ZA 9407888	A	19950524	ZA 1994-7888	19941007
	BR 9404025	A	19950613	BR 1994-4025	19941007
	HU 69031	A2	19950828	HU 1994-2900	19941007
	CN 1112553	A	19951129	CN 1994-118684	19941007
	JP 07165737	A2	19950627	JP 1994-271700	19941011
	US 5593946	A	19970114	US 1995-457252	19950601
	US 5707935	A	19980113	US 1996-699720	19960806
PRAI	EP 1993-116308		19931008		
	US 1994-318327		19941005		

OS MARPAT 123:9446
AB Title compds. [I; A = (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, aralkyl, XY(CH2)n; X = (substituted) alkyl, aryl; n = 1, 2; Y = O, S(O)m; m = 0-2; R1 = H, alkyl; R2 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl], were prepd. Thus, H2NCH2CN in H2O was treated with 2-fluorobenzoyl chloride and with aq. Na2CO3 to give 90.5% 2-fluorobenzoylaminoacetonitrile. This in MeOH at 0-5.degree. was treated with iso-Pr nitrite and then with AcCl and the mixt. was stirred at ambient temp. to give 65.4% Me 5-(2-fluorophenyl)-1,2,4-oxadiazole-3-carboxylate. This was heated with 1-phenethylamine to give 75.9% 5-(2-fluorophenyl)-1,2,4-oxadiazole-3-carboxylic acid 1-phenethylamide. The latter as a 1 kg/ha foliar spray gave complete kill of Echinochloa crus-galli.
IT **163719-94-6P 163719-96-8P 163719-97-9P**
163719-98-0P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of herbicidal 1,2,4-oxadiazolecarboxamides)
RN 163719-94-6 CAPLUS
CN 1,2,4-Oxadiazole-5-carboxamide, 3-(1,1-dimethylethyl)-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 163719-96-8 CAPLUS
CN 1,2,4-Oxadiazole-5-carboxamide, 3-(4-fluorophenyl)-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 163719-97-9 CAPLUS
CN 1,2,4-Oxadiazole-5-carboxamide, 3-(3-fluorophenyl)-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 163719-98-0 CAPLUS
CN 1,2,4-Oxadiazole-5-carboxamide, 3-(2-fluorophenyl)-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 52 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 1989:23751 CAPLUS
DN 110:23751
TI Preparation of 1-acyl-2-hydrocarbylthio-3-cyano-4H-quinolizine-4-ones as IgE inhibitors
IN Kurashina, Yoshikazu; Miyata, Hiroshi; Momose, Denichi
PA Kissei Pharmaceutical Co., Ltd., Japan
SO Eur. Pat. Appl., 58 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 277755	A1	19880810	EP 1988-300660	19880127
	R: BE, CH, DE, FR, GB, IT, LI, NL, SE				
	JP 63188676	A2	19880804	JP 1987-19734	19870130
	JP 06070036	B4	19940907		
	JP 63188677	A2	19880804	JP 1987-19735	19870130
	JP 06070037	B4	19940907		
	JP 63188678	A2	19880804	JP 1987-19736	19870130
	JP 06070038	B4	19940907		
	JP 63188679	A2	19880804	JP 1987-19737	19870130
	JP 06070039	B4	19940907		
	JP 63198680	A2	19880817	JP 1987-30603	19870212
	JP 06070040	B4	19940907		
	JP 63198681	A2	19880817	JP 1987-30604	19870212
	JP 06070041	B4	19940907		
	JP 63198682	A2	19880817	JP 1987-30605	19870212
	JP 06070042	B4	19940907		
	US 4877795	A	19891031	US 1988-147549	19880125
PRAI	JP 1987-19734		19870130		
	JP 1987-19735		19870130		
	JP 1987-19736		19870130		
	JP 1987-19737		19870130		
	JP 1987-30603		19870212		
	JP 1987-30604		19870212		
	JP 1987-30605		19870212		

OS MARPAT 110:23751
AB The title compds. (I; R1 = esterified-CO2H, CONH2, cyclic aminocarbonyl, acyl; R2 = alkyl, alkenyl, aralkyl; R3 = H, alkyl) were prepd. 2-Pyridylacetic acid hydrochloride and cyclohexylmethanol were stirred 10 h in pyridine contg. DCC to give cyclohexylmethyl 2-pyridylacetate which was heated 10 h at 120.degree. with (MeS)2C:C(CN)CO2Me to give title compd. II. Similarly prepd. 3-cyano-9-methyl-2-methylthio-1-(4-phenylpiperidinocarbonyl)-4H-quinolizin-4-one gave 50% inhibition of IgE formation at 1 .mu.g/mL by mice spleen cells in vitro with 4% inhibition of IgG formation.
IT **118183-85-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as IgE inhibitor)
RN 118183-85-0 CAPLUS
CN 4H-Quinolizine-1-carboxamide, 3-cyano-2-(methylthio)-4-oxo-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)


O
NC
N
MeS
NH
C
O

L4 ANSWER 55 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 1974:433255 CAPLUS
DN 81:33255
TI Hypoglycemic (quinoline-8-carboxamidoalkyl)benzenesulfonamide derivatives
AU Weyer, R.; Aumueller, W.; Baender, A.; Heerdt, R.; Pfaff, W.; Schweitzer, R.; Weber, H.
CS Farbwerke Hoechst A.-G., Frankfurt/M., Fed. Rep. Ger.
SO Arzneimittel-Forschung (1974), 24(3), 269-75
CODEN: ARZNAD; ISSN: 0004-4172
DT Journal
LA German
AB Seventeen quinolines I [R = H, 6-Cl, 6-Br, 5-Me, or 5-MeO; R1 = H or Me; X = CONHR2 (R2 = e.g. C3H7, cyclopentyl, cyclohexyl, 4-methylcyclohexyl, or CH2Ph) or X1 with R3 = e.g. Et, Pr, CHMe2, or cyclohexyl] had blood sugar lowering activities in rabbits. The most active compd. was N-[4-(.beta.-5-methoxyquinoline-8-carboxamidoethyl)phenylsulfonyl]-N'-cyclohexylurea (I, R = 5-MeO, R1 = H, R2 = cyclohexyl) [35401-27-5].
IT **39268-67-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and antidiabetic activity of)
RN 39268-67-2 CAPLUS
CN 8-Quinolinecarboxamide, 6-chloro-N-[1,2,3,4-tetrahydro-7-[[[5-(2-methylpropyl)-2-pyrimidinyl]amino]sulfonyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 2001:380551 CAPLUS
DN 135:5616
TI Preparation of hydrazone compounds and pesticides
IN Mita, Takeshi; Ohtsu, Tadashi; Hotta, Hiroyasu; Io, Tomoaki; Ueno, Hideki; Masuzawa, Yoshihide; Miyake, Toshiro; Mimori, Norihiko; Takii, Shinji; Itoh, Toshinori
PA Nissan Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 409 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001036381	A1	20010525	WO 2000-JP8016	20001114

W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI JP 1999-323698 A 19991115
JP 1999-323699 A 19991115
JP 2000-298021 A 20000929
JP 2000-301562 A 20001002
OS MARPAT 135:5616
AB Hydrazone compds. such as hydrazono-1,2,3,4-tetrahydronaphthalene, hydrazonoindoline, or hydrazochroman, resented by general formula (I) or salts thereof [wherein A = CH2, CH2CH2, OCH2, S(O)pCH2, S(O)pCH2CH2, or CH2 S(O)pCH2 (wherein p = 0-2), N-(un)substituted NHCH2, NHCH2CH2, or CH2NHCH2, (CH2)3, OCH2CH2; B = a single bond, O, S, (un)substituted NH, CO; G = -N:C(R5)NR6R7 (G-1), -N(R8)C(:W2)Q2 (G-2), -N:C(R5)W3-R9 (G-3); when B = O, S, (un)substituted NH, CO, G-1, or G-3, then Q1 = (halo)alkyl, (halo)cycloalkyl, (halo)alkenyl, (halo)alkynyl, (halo)cycloalkenyl, (un)substituted Ph, arom. or aliph. heterocyclyl, etc.; when B = a single bond and G = G-2, then Q1 = (halo)alkyl, (halo)cycloalkyl, (halo)alkenyl, (halo)alkynyl, (halo)cycloalkenyl, etc.; when B = a single bond or (un)substituted NH, then Q1 = H; Q2 = H, (halo)alkyl, (halo)cycloalkyl, (halo)alkenyl, (halo)alkynyl, (halo)cycloalkenyl, alkoxycarbonyl, (un)substituted benzoyl or Ph, arom. or aliph. heterocyclyl, etc.; W1, W2 = O, S; W3 = O, S, CH2; X = H, halo, cyano, isocyanato, NO2, N3, CHO, CO2H, (un)substituted carbamoyl, OH, SH, etc.; R1 = H, (halo)alkyl, cycloalkyl, cycloalkylalkyl, (halo)alkoxyalkyl, alkoxyalkoxyalkyl, benzyloxyalkyl, (halo)alkylthioalkyl, etc.; R2 = H, (halo)alkyl, alkoxyalkyl, alkylthioalkyl, cyanoalkyl, alkoxycarbonyl, (halo)alkenyl, etc.; m = 1-4] are prepd. Novel agricultural chems., in particular, insecticides and miticides contg. these compds. as the active ingredient formula I are also claimed. Thus, a soln. of tert-Bu 6-chloro-1-hydrazono-1,2,3,4-tetrahydronaphthalen-2-ylcarbamate and N,N-dimethylacetamide di-Me acetal in toluene was refluxed for 4 h to give tert-Bu 6-chloro-1-[1-(dimethylamino)ethylidenehydrazono]-1,2,3,4-tetrahydronaphthalen-2-ylcarbamate (II). II at 500 ppm controlled .gtoreq.80% Spodoptera litura larvae on cabbage leaves.
IT **340823-23-6P 340823-24-7P 340823-25-8P 340823-26-9P 340823-56-5P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except

adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of hydrazone compds. such as hydrazonotetrahydronaphthalene, hydrazonoindoline, or hydrazochroman derivs. as miticides and insecticides)

RN 340823-23-6 CAPLUS
CN 2-Thiophenecarboxamide, N-[1-[[1-(dimethylamino)ethylidene]hydrazono]-1,2,3,4-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 340823-24-7 CAPLUS
CN 3-Furancarboxamide, N-[1-[[1-(dimethylamino)ethylidene]hydrazono]-1,2,3,4-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 340823-25-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[1-[[1-(dimethylamino)ethylidene]hydrazono]-1,2,3,4-tetrahydro-2-naphthalenyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 340823-26-9 CAPLUS
CN 4-Thiazolecarboxamide, N-[1-[[1-(dimethylamino)ethylidene]hydrazono]-1,2,3,4-tetrahydro-2-naphthalenyl]-2-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 340823-56-5 CAPLUS
CN Hydrazinecarboxylic acid, [2-[[[5-chloro-1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]carbonyl]amino]-3,4-dihydro-1(2H)-naphthalenylidene]-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 2001:372159 CAPLUS
DN 134:366868
TI Preparation of benzothiazolines as neuropeptide Y receptor antagonists
IN Sato, Yoshiya; Itani, Hiromichi; Tabuchi, Seiichiro; Sakata, Yoshihiko; Ohashi, Hiroko
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 88 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2001139574	A2	20010522	JP 2000-296175	20000928
PRAI AU 1999-3093	A	19990928		

OS MARPAT 134:366868
AB The title compds. I [R1 = H, halo; W = S, O; A = (CH2)n, etc.; n = 1 - 6; Z = (un)substituted N-contg. heterocyclic ring] are prepd. 1-[(5-Chloro-2-oxobenzothiazolin-3-yl)acetyl]piperidine-4-carboxylic acid 4-benzoylanilide showed IC100 of 10-7 M in a neuropeptide Y5 receptor binding assay.
IT **340179-73-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzothiazolines as neuropeptide Y receptor antagonists)
RN 340179-73-9 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(5-chloro-2-oxo-3(2H)-benzothiazolyl)methyl]-N-(1,2,3,4-tetrahydro-1-hydroxy-7-methoxy-1-naphthalenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 16 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 2001:152650 CAPLUS
DN 134:207831
TI Preparation, composition and use of heterocyclic aromatic amides as fungicides
IN Ricks, Michael John; Dent, William Hunter, III; Rogers, Richard Brewer; Yao, Chenglin; Nader, Bassam Salim; Miesel, John Louis; Fitzpatrick, Gina Marie; Meyer, Kevin Gerald; Niyaz, Noormohamed Mohamed; Morrison, Irene Mae; Henry, Matthew James; Adamski, Butz Jenifer Lynn; Gajewski, Robert Peter
PA Dow Agrosciences LLC, USA
SO PCT Int. Appl., 200 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001014339	A2	20010301	WO 2000-US21523	20000804
	WO 2001014339	A3	20011115		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6521622	B1	20030218	US 2000-620662	20000720
	US 6355660	B1	20020312	US 2000-632930	20000804
	EP 1204643	A2	20020515	EP 2000-952599	20000804
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	EP 1234823	A2	20020828	EP 2002-9583	20000804
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	EP 1234824	A1	20020828	EP 2002-9584	20000804
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	EP 1234825	A2	20020828	EP 2002-9585	20000804
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	EP 1234826	A2	20020828	EP 2002-9586	20000804
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	EP 1234827	A2	20020828	EP 2002-9590	20000804
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	US 2002177578	A1	20021128	US 2001-22413	20011213
	US 2003018052	A1	20030123	US 2001-22207	20011213
	US 2003018012	A1	20030123	US 2001-22511	20011213
	US 2003022902	A1	20030130	US 2001-22483	20011213
	US 2003022903	A1	20030130	US 2001-23497	20011213
PRAI	US 1999-149977P	P	19990820		
	US 1999-150248P	P	19990823		
	US 2000-620662	A	20000720		
	US 1999-144676P	P	19990720		

EP 2000-952599 A3 20000804
US 2000-632930 A3 20000804
WO 2000-US21523 W 20000804

OS MARPAT 134:207831

AB Title compds. [I; wherein X1-X4 independently = O, S, NR1, N, CR2, bond; R1 = H, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, OH, CHF2,C1-4 alkoxy; R2 = H, F, Cl, Br, CN, OH, C1-3 alkyl, C1-3 haloalkyl cyclopropyl, C1-3 alkoxy; Z = O, S, NOH, NOR3; R3 = C1-3 alkyl; A = C1-14 alkyl, C1-14 alkynyl, C1-14 cycloalkyl, aryl, heteroaryl, Q; M = H, Si(t-Bu)Me2, Si(Ph)Me2, SiEt3, CZR4, SO2R5; R4 = H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl; R5 = aryl, heteroaryl, C1-6 alkyl, C2-6 alkenyl, C3-6 alkenyl, C3-6 alkynyl, C3-6 cycloalkyl; X, Y independently = O, S; W = O, CH2, bond; R = C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 cycloalkyl, aryl, heteroaryl; R11 = H, C1-3 alkyl, C2-5 alkenyl, C2-5 alkynyl; R10 = H, R, OR, OCOR, OCOOR; R8, R9 independently = H, C1-6 alkyl, C2-6 alkenyl; R6, R7 independently = H, C1-6 alkyl, C2-6 alkenyl, C2-5 alkynyl, C3-6 cycloalkyl] are prepd. as fungicides involving application methods of effective usage of title compds. to control fungi, particularly plant pathogens and wood decaying fungi. The invention also encompasses hydrates, salts and complexes thereof. The title compd. II was prepd. and tested as fungicide.

IT **321598-52-1P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and fungicidal activity of heterocyclic arom. amides)

RN 321598-52-1 CAPLUS

CN 2-Pyridinecarboxamide, 3-hydroxy-4-methoxy-N-(1,2,3,4-tetrahydro-1-oxo-2-naphthalenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 17 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 2001:78374 CAPLUS
DN 134:147596
TI 2-Arylimino-2,3-dihydrothiazoles, processes for their preparation, and their use as somatostatin receptor ligands
IN Moinet, Christophe; Sackur, Carole; Thurieau, Christophe
PA Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S, Fr.
SO PCT Int. Appl., 428 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001007424	A1	20010201	WO 2000-FR2095	20000721
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	FR 2796643	A1	20010126	FR 1999-9496	19990722
	BR 2000012647	A	20020409	BR 2000-12647	20000721
	EP 1202980	A1	20020508	EP 2000-958575	20000721
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003505453	T2	20030212	JP 2001-512509	20000721
	NO 2002000314	A	20020306	NO 2002-314	20020121
PRAI	FR 1999-9496	A	19990722		
	WO 2000-FR2095	W	20000721		

OS MARPAT 134:147596
AB The invention concerns novel 2-arylimino-2,3-dihydrothiazole derivs. I and their racemates, enantiomers, combinations, and salts [wherein R1 = (un)substituted, particularly amino-substituted alk(en/yn)yl, (hetero)aryl, aralkyl, cycloalkyl, etc.; R2 = (un)substituted carbocyclic or heterocyclic aryl; R3 = alkyl, adamantyl, (un)substituted (hetero)aryl or (hetero)aralkyl, (un)substituted carbamoyl; R4 = H, alkyl, (un)substituted (hetero)aralkyl, etc.]. Also disclosed are methods of their prepn. and their use as medicines, in particular for treating a wide variety of pathol. conditions or diseases involving somatostatin receptors. In particular, these pathol. conditions include acromegaly, pituitary adenoma, endocrine gastroenteropancreatic tumors (including the carcinoid syndrome), and gastrointestinal bleeding. Examples include 6 detailed syntheses, a listing of over 2800 characterized invention compds., and various precursor prepns. For instance, 4-H2NC6H4CH2CH2NH2 was bound to Wang resin p-nitrophenylcarbonate (at the aliph. amino group), and the resin-bound amine reacted sequentially with PhCH2CH2NCS, bromopyruvic acid, and 4-ClC6H4CH2NH2 to give, after acidic cleavage, (Z)-isomeric title compd. II. Ten selected compds. I inhibited binding of [125I-Tyr11]SRIF-14 to human somatostatin receptors in vitro with Ki < 200 nM.
IT **322747-60-4P 322747-74-0P 322747-88-6P**
322748-02-7P 322748-30-1P 322748-50-5P
322748-70-9P 322748-90-3P 322750-11-8P

322750-27-6P 322750-43-6P 322750-59-4P
322750-75-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of (arylimino)dihydrothiazoles as somatostatin receptor ligands)

RN 322747-60-4 CAPLUS
CN 4-Thiazolecarboxamide, 3-(6-aminohexyl)-2,3-dihydro-2-[(3-nitrophenyl)imino]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 322747-74-0 CAPLUS
CN 4-Thiazolecarboxamide, 3-(6-aminohexyl)-2,3-dihydro-2-[(4-phenoxyphenyl)imino]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 322747-88-6 CAPLUS
CN 4-Thiazolecarboxamide, 3-(6-aminohexyl)-2,3-dihydro-2-[[4-(1-piperidinylsulfonyl)phenyl]imino]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 322748-02-7 CAPLUS
CN 4-Thiazolecarboxamide, 3-(6-aminohexyl)-2-[(3-bromophenyl)imino]-2,3-dihydro-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 322748-30-1 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-2-[(3,5-dimethylphenyl)imino]-2,3-dihydro-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 322748-50-5 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-2,3-dihydro-2-(1-naphthalenylimino)-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 322748-70-9 CAPLUS
CN 4-Thiazolecarboxamide, 3-(5-aminopentyl)-2-[(3,5-dimethylphenyl)imino]-2,3-dihydro-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 322748-90-3 CAPLUS
CN 4-Thiazolecarboxamide, 3-(5-aminopentyl)-2,3-dihydro-2-(1-naphthalenylimino)-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 322750-11-8 CAPLUS
CN 4-Thiazolecarboxamide, 2-[[3-(aminomethyl)phenyl]imino]-2,3-dihydro-3-(2-phenylethyl)-N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 322750-27-6 CAPLUS
CN 4-Thiazolecarboxamide, 2-[[3-(aminomethyl)phenyl]imino]-2,3-dihydro-3-(2-methylpropyl)-N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 322750-43-6 CAPLUS
CN 4-Thiazolecarboxamide, 2-[[3-(aminomethyl)phenyl]imino]-2,3-dihydro-3-(1-naphthalenylmethyl)-N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 322750-59-4 CAPLUS
CN 4-Thiazolecarboxamide, 2-[[3-(aminomethyl)phenyl]imino]-3-[(4-chlorophenyl)methyl]-2,3-dihydro-N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 322750-75-4 CAPLUS
CN 4-Thiazolecarboxamide, 2-[[3-(aminomethyl)phenyl]imino]-2,3-dihydro-3-[(2-methoxyphenyl)methyl]-N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 2001:63978 CAPLUS
DN 134:131431
TI Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
IN Ricks, Michael John; Dent, William Hunter, III; Rogers, Richard Brewer; Yao, Chenglin; Nader, Bassam Salim; Miesel, John Louis; Fitzpatrick, Gina Marie; Meyer, Kevin Gerald; Niyaz, Noormohamed Mohamed; Morrison, Irene Mae; Gajewski, Robert Peter
PA Dow Agrosciences LLC, USA
SO PCT Int. Appl., 159 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001005769	A2	20010125	WO 2000-US19794	20000720
	WO 2001005769	A3	20011122		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1196388	A2	20020417	EP 2000-950470	20000720
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 6355660	B1	20020312	US 2000-632930	20000804
	US 2002177578	A1	20021128	US 2001-22413	20011213
	US 2003018052	A1	20030123	US 2001-22207	20011213
	US 2003018012	A1	20030123	US 2001-22511	20011213
	US 2003022902	A1	20030130	US 2001-22483	20011213
	US 2003022903	A1	20030130	US 2001-23497	20011213
PRAI	US 1999-144676P	P	19990720		
	US 1999-149977P	P	19990820		
	US 1999-150248P	P	19990823		
	WO 2000-US19794	W	20000720		
	US 2000-632930	A3	20000804		

OS MARPAT 134:131431
AB Title compds. I [W, X, Y, Z are selected from S, O, NR1, N, CR2 or bond and comprise a 5-6 membered (un)substituted heterocyclic ring; R1 = H, alkyl, alkenyl, alkynyl, OH, acyloxy, alkoxymethyl, CHF2, cyclopropyl, or alkoxy; R2 = H, halo, CN, OH, alkyl, haloalkyl, cyclopropyl, alkoxy, haloalkoxy, etc.; G = O, S or NOR3 where R3 = H or alkyl; A = (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, unsatd. cycloalkyl, heterocycle, bi or tricyclic ring system which may contain heteroatoms, aryl or heteroaryl, etc.] bearing a hydroxy group adjacent to the amide functionality are prepd. and disclosed as antifungal agents, particularly for plants. Thus, pyridinyl carboxamide II was prepd. via amidation of 3-benzyloxy-6-bromo-4-methoxypyridin-2-carbonyl chloride with 4-(4-trifluoromethylphenoxy)aniline with subsequent deprotection. The preferred fungicidal compn. consists of a compd. of formula I with a phytol. acceptable carrier. Activity has been demonstrated against a variety of fungi, e.g., Plasmopara viticola (Downy Mildew of Grape),

Phytophthora infestans (Late Blight of Tomato), and Venturia inaequalis (Apple Scab). I is both useful for eradication and prevention of fungal attack.

IT **321598-52-1P**

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and fungicidal activity of heterocyclic arom. amides)

RN 321598-52-1 CAPLUS

CN 2-Pyridinecarboxamide, 3-hydroxy-4-methoxy-N-(1,2,3,4-tetrahydro-1-oxo-2-naphthalenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 19 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 2001:12443 CAPLUS
DN 134:86539
TI Preparation of benzimidazolecarboxylic acid amino acid amides as I.kappa.B kinase inhibitors.
IN Ritzeler, Olaf; Stilz, Hans Ulrich; Neises, Bernhard; Bock, William Jerome, Jr.; Walser, Armin; Flynn, Gary A.
PA Aventis Pharma Deutschland Gmbh, Germany
SO PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001000610	A1	20010104	WO 2000-EP5340	20000609
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 19928424	A1	20001228	DE 1999-19928424	19990623
	DE 10006297	A1	20010816	DE 2000-10006297	20000212
	BR 2000012450	A	20020402	BR 2000-12450	20000609
	EP 1194425	A1	20020410	EP 2000-938780	20000609
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2003503400	T2	20030128	JP 2001-507019	20000609
	NO 2001006154	A	20020219	NO 2001-6154	20011217
PRAI	DE 1999-19928424	A	19990623		
	DE 2000-10006297	A	20000212		
	WO 2000-EP5340	W	20000609		

OS MARPAT 134:86539
AB Title compds. [I; 1 of R1-R4 = DNR8CHR9Z; D = CO, SO, SO2; R8 = H, alkyl; R9 = amino acid residue, (substituted) aryl, heteroaryl, heterocyclyl, alkyl, etc.; Z = (substituted) aryl, heteroaryl, heterocyclyl, etc.; the remainder of R1-R4 = H, halo, alkyl, (substituted) heteroaryl, heterocyclyl, alkyl, cyano, aralkoxy, alkoxy, etc.; R5 = H, OH, O; R6 = (substituted) aryl, Ph, heteroaryl, heterocyclyl], were prepd. Thus, 2-pyrid-4-ylbenzimidazol-4-carboxylic acid (prepn. given), H-Leu-OMe, TOTU, and (Me2CH)2EtN were stirred in MeCN to give 98% 2-pyrid-4-ylbenzimidazol-4-carbonylleucine Me ester. I inhibited I.kappa.B kinase with IC50 = 0.07-72 .mu.M.
IT **313065-41-7P 313065-61-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzimidazolecarboxylic acid amino acid amides as I.kappa.B kinase inhibitors)
RN 313065-41-7 CAPLUS
CN 2-Naphthalenecarboxylic acid, 1,2,3,4-tetrahydro-2-[[[2-(4-pyridinyl)-1H-benzimidazol-4-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 313065-61-1 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, N-[2-(aminocarbonyl)-1,2,3,4-tetrahydro-2-naphthalenyl]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 2000:908698 CAPLUS
DN 134:42443
TI Preparation and use of benzimidazole derivatives for treatment of illness.
IN Ritzeler, Olaf; Stilz, Hans Ulrich; Neises, Bernhard; Bock, William Jerome, Jr.; Walser, Armin; Flynn, Gary A.
PA Aventis Pharma Deutschland G.m.b.H., Germany
SO Ger. Offen., 36 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19928424	A1	20001228	DE 1999-19928424	19990623
	WO 2001000610	A1	20010104	WO 2000-EP5340	20000609
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	BR 2000012450	A	20020402	BR 2000-12450	20000609
	EP 1194425	A1	20020410	EP 2000-938780	20000609
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2003503400	T2	20030128	JP 2001-507019	20000609
	US 6358978	B1	20020319	US 2000-599390	20000622
	NO 2001006154	A	20020219	NO 2001-6154	20011217
PRAI	DE 1999-19928424	A	19990623		
	DE 2000-10006297	A	20000212		
	WO 2000-EP5340	W	20000609		

OS MARPAT 134:42443
AB Title compds., e.g. (I), were prepd. (no data) for use in treating diseases which feature an intensified activity by transcription factor NF.kappa.B. An example is given of solid-phase synthesis of (II). In in vitro tests, I had IC50 of 1 .mu.M for I.kappa.B-kinase, while inhibiting other kinase activities (protein kinases A and C, and casein kinase) 36, 63, and 70%, resp. In the same tests, II showed IC50 of 25 .mu.M for I.kappa.B, and inhibited the other kinases 24, 7, and 17%, resp.
IT **313065-41-7P 313065-61-1P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and use of benzimidazole derivs. for treatment of illness)
RN 313065-41-7 CAPLUS
CN 2-Naphthalenecarboxylic acid, 1,2,3,4-tetrahydro-2-[[[2-(4-pyridinyl)-1H-benzimidazol-4-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 313065-61-1 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, N-[2-(aminocarbonyl)-1,2,3,4-tetrahydro-2-naphthalenyl]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 21 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 2000:628105 CAPLUS
DN 133:222452
TI Aryl and heteroaryl amide compounds for the potentiation of cholinergic activity
IN Yamada, Akira; Aoki, Satoshi
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000051970	A1	20000908	WO 2000-JP601	20000203
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1159258	A1	20011205	EP 2000-902080	20000203
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000010225	A	20020122	BR 2000-10225	20000203
	JP 2002538132	T2	20021112	JP 2000-602198	20000203
PRAI	AU 1999-8912	A	19990226		
	WO 2000-JP601	W	20000203		

OS MARPAT 133:222452
AB Amide compds. (R1)(R2)X-Y-Q-R3 (I) and their salts are disclosed [wherein: R1, R2 = aryl or ar(lower)alkyl, or are taken together to form lower alkylene or lower alkenylene, each of which may be substituted with aryl or may be condensed with a cyclic hydrocarbon optionally substituted with lower alkyl, lower alkoxy, aryl, aryloxy or halogen; R3 = lower alkyl, lower alkoxy, aryl, arylamino or aryloxy (each of which may be substituted with lower alkoxy or halogen), pyridyl, or pyridylamino; X = CH or N; Y = bond or NH; Q = CO; with provisos]. I are potentiators of cholinergic activity, and are useful as anti-amnesia or anti-dementia agents. I are thus useful for treating a variety of central nervous system conditions, e.g., Alzheimer's dementia. For instance, reaction of 1,2,3,6-tetrahydropyridine with 4-fluorophenyl isocyanate in THF at room temp. gave title compd. II. Selected compds. I were active in a rat penile erection assay at doses of 0.1-0.32 mg/kg i.p.
IT **291756-25-7P**, 2-(Pyridin-4-ylcarbonylamino)-1,2,3,4-tetrahydronaphthalene
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of aryl and heteroaryl amide compds. as cholinergic agonists)
RN 291756-25-7 CAPLUS
CN 4-Pyridinecarboxamide, N-(1,2,3,4-tetrahydro-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 2000:368302 CAPLUS
DN 133:17388
TI Preparation of quinoline-4-carboxamides as NK-2 and NK-3 receptor ligands
IN Farina, Carlo; Giardina, Giuseppe; Grugni, Mario; Nadler, Guy Marguerite Marie Gerard; Raveglia, Luca Francesco
PA Smithkline Beecham S.p.A., Italy; Smithkline Beecham Laboratoires Pharmaceutiques
SO PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000031038	A1	20000602	WO 1999-EP9156	19991122
	W: CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1131294	A1	20010912	EP 1999-959340	19991122
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	GB 1998-25554	A	19981120		
	WO 1999-EP9156	W	19991122		

OS MARPAT 133:17388
AB The title compds. [I; R = alkyl; R1 = H or up to four optional substituents selected from alkyl, alkenyl, aryl, etc.; R2 = (CH2)nNY1Y2 (wherein n = 1-9; Y1, Y2 = H, alkyl, alkyl substituted with hydroxy, etc.; NY1Y2 = (un)substituted N-linked single or fused ring heterocyclic group); R3 = alkyl, cycloalkyl, cycloalkylalkyl, etc.; R4 = H, alkyl; CR4R = (un)substituted cycloalkyl] and their salts, useful as NK-2 or NK-3 receptor ligands, were prepd. E.g., a multi-step synthesis of (R,S)-amide I.2HCl [R = iso-Pr; R1 = H; R2 = 4-isopropylpiperazin-1-ylmethyl; R3 = Ph; R4 = Me] was given. Compds. I are effective at 100-3000 mg/day for a 70 kg adult.
IT **272104-56-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of quinoline-4-carboxamides as NK-2 and NK-3 receptor ligands)
RN 272104-56-0 CAPLUS
CN 4-Quinolinecarboxamide, 3-[(4-hydroxy[1,4'-bipiperidin]-1'-yl)methyl]-2-phenyl-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 25 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 2000:190924 CAPLUS
DN 132:237088
TI Preparation of fused pyridine inhibitors of cGMP phosphodiesterase
IN Macor, John E.; Yu, Guixue
PA Bristol-Myers Squibb Co., USA
SO PCT Int. Appl., 113 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000015222	A1	20000323	WO 1999-US21070	19990913
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6326379	B1	20011204	US 1999-393833	19990910
CA 2342583	AA	20000323	CA 1999-2342583	19990913
AU 9961438	A1	20000403	AU 1999-61438	19990913
AU 751486	B2	20020815		
EP 1113796	A1	20010711	EP 1999-948211	19990913
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI US 1998-100665P	P	19980916		
WO 1999-US21070	W	19990913		

OS MARPAT 132:237088
AB The title compds. [I or II; E1 = OR1, SR1, NH-A1-cycloalkyl, etc.; E2 = NH-A1-alkoxy, NH-A1-CO2alkyl, NH-A1-aryl, etc.; R1 = A1-cycloalkyl, A1-alkoxy, A1-aryl, etc.; X1 = OA1R2, OR9, NR9R10, etc.; X2 = OA1R25, N(R5)A2R25. etc.; X3 = OR9, OA1OR9, NR9R10, etc.; A1 = (un)substituted alkylene; Y = N, CR6; Z = N, CR7 with the proviso that at least one of Y and Z = N; R3 = H, alkyl, cycloalkyl, etc.; R6, R7 = H, alkyl, cycloalkyl, etc.; R4 = H, 1- or 3-imidazolyl, etc.; A2 = a direct bond, alkylene, alkenyl, etc.; R2 = cycloalkyl, aryl, heteroaryl, etc.; R25 = cycloalkyl, aryl, heteroaryl, etc.; R5 = H, alkyl, cycloalkyl, etc.; R9, R10 = H, alkyl, cycloalkyl, etc.], useful for treating a cGMP PDE (esp. type V) assocd. condition such as erectile dysfunction, were prepd. Thus, reacting 4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid with 4-aminomethylpyridine in the presence of EDAC.HCl, 1-hydroxybenzotriazole and Et3N in THF afforded 90% II [Y = N; Z = CH; E2 = 3-Cl-4-MeOC6H3CH2NH; X2 = 4-pyridynylmethylamino; R3 = Et; R4 = H]. Compds. I are effective at 0.05-100 mg/kg/day.
IT **261770-72-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of fused pyridine inhibitors of cGMP phosphodiesterase)
RN 261770-72-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[(3-chloro-4-methoxyphenyl)methyl]amino]-1-ethyl-N-(1,2,3,4-tetrahydro-1-naphthalenyl)-

(9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 26 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 2000:161121 CAPLUS
DN 132:207763
TI Preparation of benzopyran, tetrahydroquinoline, pyrano[2,3-b]pyridine, and indan derivatives as potassium channel inhibitors
IN Lloyd, John; Finlay, Heather J.; Vaccaro, Wayne; Atwal, Karnail; Gross, Michael F.; Spear, Kerry L.
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 210 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000012077	A1	20000309	WO 1999-US18599	19990816
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2341678	AA	20000309	CA 1999-2341678	19990816
	AU 9956753	A1	20000321	AU 1999-56753	19990816
	AU 754204	B2	20021107		
	EP 1109544	A1	20010627	EP 1999-943714	19990816
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002523451	T2	20020730	JP 2000-567195	19990816
	US 6150356	A	20001121	US 1999-375955	19990817
	US 6511977	B1	20030128	US 2000-670285	20000925
PRAI	US 1998-98709P	P	19980901		
	WO 1999-US18599	W	19990816		
	US 1999-375955	A3	19990817		

OS MARPAT 132:207763
AB The title compds. (I) [wherein A, B, and D = independently CH or N; R = H, (aryl)alkyl, alkenyl, aryl, (hetero)cycloalkyl, or cycloalkylalkyl; R1 = (aryl)alkyl, aryl, alkenyl, heterocyclo, NR5-heterocyclo, (hetero)cycloalkyl, cycloalkylalkyl, or (un)substituted amino; or R and R1 taken together with the N-S atoms = a 5- to 8-membered ring; R2 = H, (aryl)alkyl, acyl, carboxymethyl, carbamoylmethyl, etc.; R3 and R4 = independently = H, (aryl)alkyl, cycloalkyl, or R3 and R4 taken together with the C to which they are attached form a 5- to 8-membered ring; R5 = H, (aryl)alkyl, alkenyl, aryl, or cycloalkyl(alkyl); X1 = (CR3R4)n, O, NR5, S, S(O), SO2, -OCR3R4-, -NR5CR3R4-, -SCR3R4-, -S(O)CR3R4-, or -SO2CR3R4-; n = 1-3; X2 = single bond, NR5, or O; Q = substituted NHCH:NCN, acyl, (un)substituted sulfamoyl, or substituted heterocyclo] were prepd by soln. phase or solid phase synthesis as antiarrhythmics. For example, II was formed in a 3-step sequence involving: (1) sulfonylation of (trans)-4-amino-3,4-dihydro-2,2-dimethyl-6-cyano-2H-benzopyran with 4-ethylbenzenesulfonyl chloride (85%), (2) hydrolysis of the nitrile to the carboxylic acid using aq. Na2O2 (33%), and (3) amidation with 1,2,3,4-tetrahydro-1-naphthylamine (51%). I block the delayed rectifier voltage-gated K+ channel (IKur) and are therefore useful in the prevention and treatment of cardiac arrhythmia (no data).

IT **260397-93-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compd.; prepn. of arylsulfamido benzopyran, tetrahydroquinoline, pyrano[2,3-b]pyridine, and indan derivs. by soln. phase or solid phase synthesis as potassium channel inhibitors for the treatment of arrhythmia)

RN 260397-93-1 CAPLUS

CN 2H-1-Benzopyran-6-carboxamide, 4-[[(4-ethylphenyl)sulfonyl]amino]-3,4-dihydro-3-hydroxy-2,2-dimethyl-N-(1,2,3,4-tetrahydro-1-naphthalenyl)-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 28 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 1999:404951 CAPLUS
DN 131:58850
TI Preparation of quinolinepiperazine and quinolinepiperidine derivatives and their use as combined 5-HT1A, 5-HT1B, and 5-HT1D receptor antagonists
IN Gaster, Laramie Mary
PA Smithkline Beecham Plc, UK
SO PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9931086	A1	19990624	WO 1998-EP7804	19981202
	W: CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2313125	AA	19990624	CA 1998-2313125	19981202
	EP 1047691	A1	20001102	EP 1998-965729	19981202
	R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
	JP 2002508366	T2	20020319	JP 2000-539010	19981202
PRAI	GB 1997-26364	A	19971212		
	GB 1997-26905	A	19971219		
	GB 1998-317	A	19980107		
	WO 1998-EP7804	W	19981202		

OS MARPAT 131:58850
AB The title compds. I [Ra = substituted Ph, bicyclic aryl, heterocyclyl, etc.; L = YC(O)DG, C(O)DG, DGC(O) in which Y is -NH-, NR5 where R5 is C1-6alkyl, or Y is -CH2- or -O-; D is nitrogen, carbon or a CH group, or G is hydrogen or C1-6alkyl providing that D is nitrogen or a CH group, or G together with Rb1 forms a group W where W is (CR16R17)t where t is 2, 3 or 4 and R16 and R17 are independently hydrogen or C1-6alkyl or W is (CR16R17)u-J where u is 0, 1, 2 or 3 and J is oxygen, sulfur, CR16:CR17, CR16:N, :CR16O, :CR16S or :CR16NR17 provided that u is not 0 when J is oxygen or sulfur; X is nitrogen or carbon; Rb1, Rb2 and Rb3 are independently hydrogen, halogen, hydroxy, C1-6alkyl, C2-6alkenyl, C3-6cycloalkyl, trifluoromethyl, C1-6alkoxy or aryl, or Rb1 together with G forms a group W as defined above; Rc is hydrogen or C1-6alkyl] were prepd. E.g., N-[4-(4-methylpiperazin-1-yl)quinolin-6-yl]-N'-[5-(pyridin-4-yl)naphth-1-yl]urea was prepd. Some examples of I had pKi values > 8.5 at 5-HT1A, 5-HT1B, and 5-HT1D receptors.
IT **227956-57-2P 227956-71-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of quinolinepiperazine and quinolinepiperidine derivs. and their use as combined 5-HT1A, 5-HT1B, and 5-HT1D receptor antagonists)
RN 227956-57-2 CAPLUS
CN Pyrido[2,3-g]quinoline-1(2H)-carboxamide, 3,4-dihydro-9-(4-methyl-1-piperazinyl)-N-(1,2,3,4-tetrahydro-1-oxo-2-naphthalenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 227956-71-0 CAPLUS
CN Pyrido[2,3-g]quinoline-1(2H)-carboxamide, 3,4-dihydro-9-(4-methyl-1-piperazinyl)-N-(1,2,3,4-tetrahydro-1-oxo-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 29 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 1999:396632 CAPLUS
DN 131:208606
TI A new class of dipeptide derivatives that are potent and selective .delta. opioid agonists
AU Schiller, P. W.; Weltrowska, G.; Berezowska, I.; Lemieux, C.; Chung, N. N.; Carpenter, K. A.; Wilkes, B. C.
CS Clinical Research Institute of Montreal, Montreal, QC, H2W 1R7, Can.
SO Peptides: Frontiers of Peptide Science, Proceedings of the American Peptide Symposium, 15th, Nashville, June 14-19, 1997 (1999), Meeting Date 1997, 514-516. Editor(s): Tam, James P.; Kaumaya, Pravin T. P. Publisher: Kluwer, Dordrecht, Neth.
CODEN: 67UCAR
DT Conference
LA English
AB A new class of potent and selective .delta.-opioid agonists has been developed by alteration of dipeptides having the general formula H-Tyr-Tic-NH-(CH2)n-Ph. Structure-activity data are presented for 18 dipeptides (displacement of DAMGO vs. DSLET from rat brain membrane binding sites).
IT **209786-88-9 209786-89-0**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dipeptide derivs. that are potent and selective .delta. opioid agonists)
RN 209786-88-9 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[(2S)-2-amino-3-(4-hydroxyphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-N-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209786-89-0 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[(2S)-2-amino-3-(4-hydroxyphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-N-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 31 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 1999:354484 CAPLUS
DN 131:31954
TI Preparation of quinoxalinecarboxamides and analogs as metabotropic glutamate receptor antagonists
IN Van Wagenen, Bradford C.; Moe, Scott T.; Smith, Daryl L.; Sheehan, Susan M.; Shcherbakova, Irina; Travato, Richard; Walton, Ruth; Barmore, Robert; Delmar, Eric G.; Stormann, Thomas M.
PA NPS Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9926927	A2	19990603	WO 1998-US24833	19981120
	WO 9926927	A3	19991021		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2311131	AA	19990603	CA 1998-2311131	19981120
	AU 9915317	A1	19990615	AU 1999-15317	19981120
	EP 1037878	A2	20000927	EP 1998-959535	19981120
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2001524468	T2	20011204	JP 2000-522085	19981120
	US 6429207	B1	20020806	US 2000-573347	20000519
	US 2003013715	A1	20030116	US 2002-211523	20020805
PRAI	US 1997-66758P	P	19971121		
	WO 1998-US24833	W	19981120		
	US 1999-137272P	P	19990602		
	US 2000-573347	A3	20000519		

OS MARPAT 131:31954
AB RZR1 [R = (ar)alkyl, (alkyl)cycloalkyl; R1 = (hetero)aryl(alkyl); Z = (CO- and heteroatom-interrupted)(CH2)2-6, -alkenylene, -alkynylene] were prepd. as metabotropic glutamate receptor antagonists (no data). Thus, 2-quinoxalinecarboxylic acid was amidated by 2-adamantanamine to give N-(2-adamantyl)-2-quinoxalinecarboxamide.
IT **226878-89-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of quinoxalinecarboxamides and analogs as metabotropic glutamate receptor antagonists)
RN 226878-89-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


O
N
N
H
S
N

L4 ANSWER 32 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 1998:709058 CAPLUS
DN 129:343423
TI 2-Benzoyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide derivatives and their use as inhibitors of hepatic production of ApoB-100
IN Daugan, Alain Claude-Marie; Pianetti, Pascal Maurice Charles
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DT Patent
LA English

not fully aromatic!

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9847877	A1	19981029	WO 1998-EP2244	19980420
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9875265	A1	19981113	AU 1998-75265	19980420
PRAI	GB 1997-8119		19970422		
	WO 1998-EP2244		19980420		

OS MARPAT 129:343423

AB The invention relates to compds. I [wherein R0 = H, halo, C1-4 alkyl, C1-4 alkoxy, or methylenedioxy; n = 1-4; R1 = H, halo, C1-4 alkyl, C1-4 alkoxy, CF3O, or methylenedioxy; p = 1-4; R2 = H, halo, C1-4 alkyl, C1-4 alkoxy, methylenedioxy, NR4R5, -(C1-4 alkylene)-NR6R7, -NR4- or -O-(C1-4 alkylene)-NR8R9, 4-morpholino, or 4-R10-piperazin-1-yl, m = 1-4; R3 = H or C1-4 alkyl; R4-R10 = H or C1-4 alkyl] and their pharmaceutically acceptable salts or solvates, to processes for their prepn., and their use in the treatment of conditions mediated by ApoB-100 regulation. In particular, as inhibitors of hepatic ApoB-100 prodn., I are of use in treatment of pancreatitis, NIDDM, coronary heart disease, hyperlipidemia, and hypercholesterolemia. For instance, (+)-7-methyl-1,2,3,4-tetrahydronaphthalen-1-ylamine (resoln. given) was coupled with 2-BOC-D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid using EDC and HOBT, and the resultant amide was deprotected with CF3CO2H and coupled with 4-MeC6H4CO2H under similar conditions to give title compd. II (+)-isomer. In a test for potency and selectivity, II inhibited prodn. of ApoB-100 in HepG2 cells in vitro with an IC50 of 0.9 nM, but showed an IC50 of > 5000 nM toward ApoA-1 prodn. in the same assay. Almost 50 compds. were prepd., and their stereo-unspecified forms were claimed. Approx. 60 intermediates were prepd., 7 compds. were bioassayed, and 21 pharmaceutical formulations were listed.

IT **215315-48-3P 215315-49-4P 215315-50-7P**
215315-51-8P 215315-67-6P 215315-68-7P
215315-69-8P 215315-70-1P 215315-72-3P
215315-73-4P 215315-74-5P 215315-76-7P
215315-78-9P 215315-80-3P 215315-85-8P
215315-87-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of benzoyltetrahydroisoquinolinecarboxamide derivs. as inhibitors of hepatic prodn. of ApoB-100)

RN 215315-48-3 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-3-[[(1,2,3,4-tetrahydro-7-methyl-1-naphthalenyl)amino]carbonyl]-, 1,1-dimethylethyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215315-49-4 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-3-[[(1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)amino]carbonyl]-, 1,1-dimethylethyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215315-50-7 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-N-(1,2,3,4-tetrahydro-7-methyl-1-naphthalenyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215315-51-8 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-N-(1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215315-67-6 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-3-[[[1,2,3,4-tetrahydro-7-(1-methylethyl)-1-naphthalenyl]amino]carbonyl]-, 1,1-dimethylethyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215315-68-7 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 3-[[[7-(1,1-dimethylethyl)-1,2,3,4-

tetrahydro-1-naphthalenyl]amino]carbonyl]-3,4-dihydro-, 1,1-dimethylethyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215315-69-8 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-3-[[(1,2,3,4-tetrahydro-1-naphthalenyl)amino]carbonyl]-, 1,1-dimethylethyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215315-70-1 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-3-[[(1,2,3,4-tetrahydro-5,7-dimethyl-1-naphthalenyl)amino]carbonyl]-, 1,1-dimethylethyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215315-72-3 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 3-[[(6-fluoro-1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)amino]carbonyl]-3,4-dihydro-, 1,1-dimethylethyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215315-73-4 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-N-[1,2,3,4-tetrahydro-7-(1-methylethyl)-1-naphthalenyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215315-74-5 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[7-(1,1-dimethylethyl)-1,2,3,4-tetrahydro-1-naphthalenyl]-1,2,3,4-tetrahydro-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215315-76-7 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-N-(1,2,3,4-tetrahydro-1-naphthalenyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215315-78-9 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-3-[[[(1R)-1,2,3,4-tetrahydro-5,7-dimethyl-1-naphthalenyl]amino]carbonyl]-, 1,1-dimethylethyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215315-80-3 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-3-[[[(1S)-1,2,3,4-tetrahydro-5,7-dimethyl-1-naphthalenyl]amino]carbonyl]-, 1,1-dimethylethyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215315-85-8 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 3-[[[(1R)-6-fluoro-1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl]amino]carbonyl]-3,4-dihydro-, 1,1-dimethylethyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215315-87-0 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 3-[[[(1S)-6-fluoro-1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl]amino]carbonyl]-3,4-dihydro-, 1,1-dimethylethyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **215314-12-8P 215314-13-9P 215314-14-0P**
215314-15-1P 215314-16-2P 215314-17-3P
215314-18-4P 215314-19-5P 215314-20-8P
215314-21-9P 215314-23-1P 215314-26-4P
215314-27-5P 215314-29-7P 215314-31-1P
215314-32-2P 215314-34-4P 215314-40-2P
215314-42-4P 215314-45-7P 215314-46-8P
215314-48-0P 215314-50-4P 215314-52-6P
215314-54-8P 215314-55-9P 215314-56-0P
215314-58-2P 215314-60-6P 215314-62-8P
215314-64-0P 215314-66-2P 215314-68-4P
215314-70-8P 215314-72-0P 215314-73-1P
215314-75-3P 215314-77-5P 215314-79-7P
215314-82-2P 215314-84-4P 215314-87-7P
215314-89-9P 215314-91-3P 215314-93-5P
215314-95-7P 215314-97-9P 215314-99-1P
215315-01-8P 215315-02-9P 215315-04-1P
215315-05-2P 215315-06-3P 215315-07-4P

215315-08-5P 215315-09-6P 215315-11-0P
215315-13-2P 215315-15-4P 215315-16-5P
215315-19-8P 215315-20-1P 215315-21-2P
215315-22-3P 215315-23-4P 215315-24-5P
215315-25-6P 215315-26-7P 215315-27-8P
215315-28-9P 215315-29-0P 215315-30-3P
215315-31-4P 215315-32-5P 215315-33-6P
215315-34-7P 215315-35-8P 215315-36-9P
215315-37-0P 215315-38-1P 215315-39-2P
215315-40-5P 215315-41-6P 215315-42-7P
215315-43-8P 215315-44-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(product; prepn. of benzoyltetrahydroisoquinolinecarboxamide derivs. as inhibitors of hepatic prodn. of ApoB-100)

RN 215314-12-8 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-(4-methylbenzoyl)-N-(1,2,3,4-tetrahydro-7-methyl-1-naphthalenyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215314-13-9 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[3-(dimethylamino)-4-methylbenzoyl]-1,2,3,4-tetrahydro-N-(1,2,3,4-tetrahydro-7-methyl-1-naphthalenyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215314-14-0 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[3-(dimethylamino)benzoyl]-1,2,3,4-tetrahydro-N-(1,2,3,4-tetrahydro-7-methyl-1-naphthalenyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215314-15-1 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)benzoyl]-N-(1,2,3,4-tetrahydro-7-methyl-1-naphthalenyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215314-16-2 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)benzoyl]-N-(1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215314-17-3 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[3-(dimethylamino)benzoyl]-1,2,3,4-tetrahydro-N-(1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215314-18-4 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[3-[2-(dimethylamino)ethoxy]benzoyl]-1,2,3,4-tetrahydro-N-[1,2,3,4-tetrahydro-7-(1-methylethyl)-1-naphthalenyl]-, (3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215314-19-5 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[3-[2-(dimethylamino)ethoxy]benzoyl]-1,2,3,4-tetrahydro-N-(1,2,3,4-tetrahydro-7-methyl-1-naphthalenyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215314-20-8 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[3-[2-(dimethylamino)ethoxy]benzoyl]-1,2,3,4-tetrahydro-N-(1,2,3,4-tetrahydro-5,7-dimethyl-1-naphthalenyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215314-21-9 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-(4-methylbenzoyl)-N-[1,2,3,4-tetrahydro-7-(1-methylethyl)-1-naphthalenyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215314-23-1 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-(1,3-benzodioxol-5-ylcarbonyl)-1,2,3,4-tetrahydro-N-(1,2,3,4-tetrahydro-7-methyl-1-naphthalenyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215314-26-4 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)benzoyl]-N-[1,2,3,4-tetrahydro-7-(1-methylethyl)-1-naphthalenyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215314-27-5 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[3-[2-(diethylamino)ethoxy]benzoyl]-1,2,3,4-tetrahydro-N-[1,2,3,4-tetrahydro-7-(1-methylethyl)-1-naphthalenyl]-, (3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215314-29-7 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[7-(1,1-dimethylethyl)-1,2,3,4-tetrahydro-1-naphthalenyl]-1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)benzoyl]-, (3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215314-31-1 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[3-[2-(dimethylamino)ethoxy]benzoyl]-N-[7-(1,1-dimethylethyl)-1,2,3,4-tetrahydro-1-naphthalenyl]-1,2,3,4-tetrahydro-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 215314-32-2 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[3-[3-(dimethylamino)propoxy]benzoyl]-1,2,3,4-tetrahydro-N-[1,2,3,4-tetrahydro-7-(1-methylethyl)-1-naphthalenyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 215314-34-4 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[3-[2-[bis(1-methylethyl)amino]ethoxy]benzoyl]-1,2,3,4-tetrahydro-N-[1,2,3,4-tetrahydro-7-(1-methylethyl)-1-naphthalenyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 215314-40-2 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-(4-methylbenzoyl)-N-(1,2,3,4-tetrahydro-5,7-dimethyl-1-naphthalenyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215314-42-4 CAPLUS
CN 3-Isoquinolinecarboxamide, N-(6-fluoro-1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)-1,2,3,4-tetrahydro-2-(4-methylbenzoyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215314-45-7 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-(3-methoxybenzoyl)-N-(1,2,3,4-tetrahydro-7-methyl-1-naphthalenyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215314-46-8 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[3-(4-methyl-1-piperazinyl)benzoyl]-N-(1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215314-48-0 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[3-(dimethylamino)-4-methoxybenzoyl]-1,2,3,4-tetrahydro-N-(1,2,3,4-tetrahydro-7-methyl-1-naphthalenyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215314-50-4 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-(4-chlorobenzoyl)-1,2,3,4-tetrahydro-N-(1,2,3,4-tetrahydro-7-methyl-1-naphthalenyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215314-52-6 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)benzoyl]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215314-54-8 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[2-(dimethylamino)benzoyl]-1,2,3,4-tetrahydro-N-(1,2,3,4-tetrahydro-1-naphthalenyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215314-55-9 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[3-[2-(dimethylamino)propoxy]benzoyl]-1,2,3,4-tetrahydro-N-[1,2,3,4-tetrahydro-7-(1-methylethyl)-1-naphthalenyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 215314-56-0 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[3-[2-(dimethylamino)-1-methylethoxy]benzoyl]-1,2,3,4-tetrahydro-N-[1,2,3,4-tetrahydro-7-(1-methylethyl)-1-naphthalenyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 215314-58-2 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[3-[2-(dimethylamino)-2-methylpropoxy]benzoyl]-1,2,3,4-tetrahydro-N-[1,2,3,4-tetrahydro-7-(1-methylethyl)-1-naphthalenyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215314-60-6 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[3-[2-(dimethylamino)-1,1-dimethylethoxy]benzoyl]-1,2,3,4-tetrahydro-N-[1,2,3,4-tetrahydro-7-(1-methylethyl)-1-naphthalenyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 215314-62-8 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)benzoyl]-N-[(1R)-1,2,3,4-tetrahydro-4,4,7-trimethyl-1-naphthalenyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 215314-64-0 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)benzoyl]-N-[(1S)-1,2,3,4-tetrahydro-4,4,7-trimethyl-1-naphthalenyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 215314-66-2 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)benzoyl]-N-[(1R)-1,2,3,4-tetrahydro-4,4,6-trimethyl-1-naphthalenyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 215314-68-4 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)benzoyl]-N-[(1S)-1,2,3,4-tetrahydro-4,4,6-trimethyl-1-naphthalenyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 215314-70-8 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)benzoyl]-N-[(1R)-1,2,3,4-tetrahydro-7-methoxy-4,4-dimethyl-1-naphthalenyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 215314-72-0 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)benzoyl]-N-[(1S)-1,2,3,4-tetrahydro-7-methoxy-4,4-dimethyl-1-naphthalenyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 215314-73-1 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)benzoyl]-N-[(1R)-1,2,3,4-tetrahydro-3,3-dimethyl-1-naphthalenyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 215314-75-3 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)benzoyl]-N-[(1S)-1,2,3,4-tetrahydro-3,3-dimethyl-1-naphthalenyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 215314-77-5 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[3-(dimethylamino)benzoyl]-1,2,3,4-tetrahydro-N-[(1R)-1,2,3,4-tetrahydro-7-methoxy-4,4-dimethyl-1-naphthalenyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 215314-79-7 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[3-(dimethylamino)benzoyl]-1,2,3,4-tetrahydro-N-[(1S)-1,2,3,4-tetrahydro-7-methoxy-4,4-dimethyl-1-naphthalenyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 215314-82-2 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)benzoyl]-N-[(1R)-1,2,3,4-tetrahydro-5,7-dimethyl-1-naphthalenyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 215314-84-4 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)benzoyl]-N-[(1S)-1,2,3,4-tetrahydro-5,7-dimethyl-1-naphthalenyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 215314-87-7 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)benzoyl]-N-[1,2,3,4-tetrahydro-7-(trifluoromethoxy)-1-naphthalenyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215314-89-9 CAPLUS
CN 3-Isoquinolinecarboxamide, N-(7-fluoro-1,2,3,4-tetrahydro-1-naphthalenyl)-1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)benzoyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215314-91-3 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-(4-methylbenzoyl)-N-(1,2,3,4-tetrahydro-7-methyl-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 215314-93-5 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[3-(dimethylamino)-4-methylbenzoyl]-1,2,3,4-tetrahydro-N-(1,2,3,4-tetrahydro-7-methyl-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 215314-95-7 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[3-(dimethylamino)benzoyl]-1,2,3,4-tetrahydro-N-(1,2,3,4-tetrahydro-7-methyl-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 215314-97-9 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)benzoyl]-

N-(1,2,3,4-tetrahydro-7-methyl-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 215314-99-1 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)benzoyl]-N-(1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 215315-01-8 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[3-(dimethylamino)benzoyl]-1,2,3,4-tetrahydro-N-(1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 215315-02-9 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[3-[2-(dimethylamino)ethoxy]benzoyl]-1,2,3,4-tetrahydro-N-[1,2,3,4-tetrahydro-7-(1-methylethyl)-1-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 215315-04-1 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[3-[2-(dimethylamino)ethoxy]benzoyl]-1,2,3,4-tetrahydro-N-(1,2,3,4-tetrahydro-7-methyl-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 215315-05-2 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[3-[2-(dimethylamino)ethoxy]benzoyl]-1,2,3,4-tetrahydro-N-(1,2,3,4-tetrahydro-5,7-dimethyl-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 215315-06-3 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-(4-methylbenzoyl)-N-[1,2,3,4-tetrahydro-7-(1-methylethyl)-1-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 215315-07-4 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-(1,3-benzodioxol-5-ylcarbonyl)-1,2,3,4-tetrahydro-N-(1,2,3,4-tetrahydro-7-methyl-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 215315-08-5 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)benzoyl]-N-[1,2,3,4-tetrahydro-7-(1-methylethyl)-1-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 215315-09-6 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[3-[2-(diethylamino)ethoxy]benzoyl]-1,2,3,4-tetrahydro-N-[1,2,3,4-tetrahydro-7-(1-methylethyl)-1-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 215315-11-0 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[7-(1,1-dimethylethyl)-1,2,3,4-tetrahydro-1-naphthalenyl]-1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)benzoyl]- (9CI) (CA INDEX NAME)



RN 215315-13-2 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[3-[2-(dimethylamino)ethoxy]benzoyl]-N-[7-(1,1-dimethylethyl)-1,2,3,4-tetrahydro-1-naphthalenyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



RN 215315-15-4 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[3-[3-(dimethylamino)propoxy]benzoyl]-1,2,3,4-tetrahydro-N-[1,2,3,4-tetrahydro-7-(1-methylethyl)-1-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 215315-16-5 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[3-[2-[bis(1-methylethyl)amino]ethoxy]benzoyl]-1,2,3,4-tetrahydro-N-[1,2,3,4-tetrahydro-7-(1-methylethyl)-1-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 215315-19-8 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-(4-methylbenzoyl)-N-(1,2,3,4-tetrahydro-5,7-dimethyl-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 215315-20-1 CAPLUS
CN 3-Isoquinolinecarboxamide, N-(6-fluoro-1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)-1,2,3,4-tetrahydro-2-(4-methylbenzoyl)- (9CI) (CA INDEX NAME)



RN 215315-21-2 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-(3-methoxybenzoyl)-N-(1,2,3,4-tetrahydro-7-methyl-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 215315-22-3 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[3-(4-methyl-1-piperazinyl)benzoyl]-N-(1,2,3,4-tetrahydro-7-methoxy-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 215315-23-4 CAPLUS

CN 3-Isoquinolinecarboxamide, 2-[3-(dimethylamino)-4-methoxybenzoyl]-1,2,3,4-tetrahydro-N-(1,2,3,4-tetrahydro-7-methyl-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 215315-24-5 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-(4-chlorobenzoyl)-1,2,3,4-tetrahydro-N-(1,2,3,4-tetrahydro-7-methyl-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 215315-25-6 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)benzoyl]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 215315-26-7 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[2-(dimethylamino)benzoyl]-1,2,3,4-tetrahydro-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 215315-27-8 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)benzoyl]-N-[(1R)-1,2,3,4-tetrahydro-4,4,7-trimethyl-1-naphthalenyl]-, (3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 215315-28-9 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)benzoyl]-N-[(1R)-1,2,3,4-tetrahydro-4,4,7-trimethyl-1-naphthalenyl]-, (3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 215315-29-0 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)benzoyl]-N-[(1R)-1,2,3,4-tetrahydro-4,4,6-trimethyl-1-naphthalenyl]-, (3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 215315-30-3 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)benzoyl]-N-[(1R)-1,2,3,4-tetrahydro-4,4,6-trimethyl-1-naphthalenyl]-, (3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 215315-31-4 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)benzoyl]-N-[(1R)-1,2,3,4-tetrahydro-7-methoxy-4,4-dimethyl-1-naphthalenyl]-, (3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 215315-32-5 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)benzoyl]-N-[(1R)-1,2,3,4-tetrahydro-7-methoxy-4,4-dimethyl-1-naphthalenyl]-, (3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 215315-33-6 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)benzoyl]-N-[(1R)-1,2,3,4-tetrahydro-3,3-dimethyl-1-naphthalenyl]-, (3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 215315-34-7 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)benzoyl]-N-[(1R)-1,2,3,4-tetrahydro-3,3-dimethyl-1-naphthalenyl]-, (3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 215315-35-8 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[3-(dimethylamino)benzoyl]-1,2,3,4-tetrahydro-N-[(1R)-1,2,3,4-tetrahydro-7-methoxy-4,4-dimethyl-1-naphthalenyl]-, (3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 215315-36-9 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[3-(dimethylamino)benzoyl]-1,2,3,4-tetrahydro-N-[(1R)-1,2,3,4-tetrahydro-7-methoxy-4,4-dimethyl-1-naphthalenyl]-, (3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 215315-37-0 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)benzoyl]-N-[(1R)-1,2,3,4-tetrahydro-5,7-dimethyl-1-naphthalenyl]-, (3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 215315-38-1 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)benzoyl]-N-[(1R)-1,2,3,4-tetrahydro-5,7-dimethyl-1-naphthalenyl]-, (3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 215315-39-2 CAPLUS
CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)benzoyl]-N-[1,2,3,4-tetrahydro-7-(trifluoromethoxy)-1-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 215315-40-5 CAPLUS
CN 3-Isoquinolinecarboxamide, N-(7-fluoro-1,2,3,4-tetrahydro-1-naphthalenyl)-1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)benzoyl]- (9CI) (CA INDEX NAME)



RN 215315-41-6 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[3-[2-(dimethylamino)propoxy]benzoyl]-1,2,3,4-tetrahydro-N-[1,2,3,4-tetrahydro-7-(1-methylethyl)-1-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 215315-42-7 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[3-[2-(dimethylamino)-1-methylethoxy]benzoyl]-1,2,3,4-tetrahydro-N-[1,2,3,4-tetrahydro-7-(1-methylethyl)-1-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 215315-43-8 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[3-[2-(dimethylamino)-2-methylpropoxy]benzoyl]-1,2,3,4-tetrahydro-N-[1,2,3,4-tetrahydro-7-(1-methylethyl)-1-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 215315-44-9 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[3-[2-(dimethylamino)-1,1-dimethylethoxy]benzoyl]-1,2,3,4-tetrahydro-N-[1,2,3,4-tetrahydro-7-(1-methylethyl)-1-naphthalenyl]- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 33 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 1998:479553 CAPLUS
DN 129:95725
TI Preparation of dipeptide derivatives for treatment of pain
IN Schiller, Peter
PA Astra AB (Publ), Swed.
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9828327	A1	19980702	WO 1997-SE2156	19971218
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9855808	A1	19980717	AU 1998-55808	19971218
	AU 721131	B2	20000622		
	EP 946588	A1	19991006	EP 1997-952145	19971218
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2001507026	T2	20010529	JP 1998-528696	19971218
	US 6150335	A	20001121	US 1998-43881	19980401
	NO 9903069	A	19990621	NO 1999-3069	19990621
PRAI	SE 1996-4789	A	19961220		
	WO 1997-SE2156	W	19971218		

OS MARPAT 129:95725
AB Dipeptide derivs. I [R1, R2 = independently H, Me(CH2)n, Ph(CH2)m, cyclopropylmethyl, allyl; R3-R6 = H; R3 = C1-6 alkyl, R4-R6 = H; R3 = R6 = C1-6 alkyl, R4 = R5 = H; R3 = R5 = R6 = H, R4 = F, Cl, Br, iodo, OH, NO2, NH2; R7 = (un)substituted 2-phenylethyl or 2-cyclohexylethyl; n = 0-12; m = 1-3] are claimed for the manuf. of a medicament for the treatment of pain. The compds. are .delta. opioid agonists and thus useful in the treatment of pain without the requirement of co-application of a .mu. opioid agonist. Thus, amidation of Boc-Tic-OH (Boc = Me3CO2C; Tic = L-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid) with 2,2-diphenylethylamine, deprotection, peptide coupling with Boc-Tyr(Boc)-OH, and final deprotection gave desired dipeptide deriv. H-Tyr-Tic-NHCH2CHPh2 (II). II and related dipeptide derivs. are selective .delta. opioid agonists, with II having Ki = 0.981 nM in a .delta. opioid receptor assay.
IT **209786-88-9P 209786-89-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of dipeptide derivs. for treatment of pain)
RN 209786-88-9 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[(2S)-2-amino-3-(4-hydroxyphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-N-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209786-89-0 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[(2S)-2-amino-3-(4-hydroxyphenyl)-1-oxopropyl]-1,2,3,4-tetrahydro-N-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 34 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 1998:319981 CAPLUS
DN 129:54341
TI 5-Fluorouracil derivatives. XXIII. Synthesis and antitumor activities of 1-carbamoyl-5-fluorouracils having an aromatic ring
AU Ozaki, Shoichiro; Kong, Xiang-Zheng; Watanabe, Yutaka; Hoshiko, Tomonori; Ogasawara, Tomio; Ueno, Takao; Furukawa, Uiroyuki; Iigo, Masaaki; Hoshi, Akio
CS Department of Chemistry, Shangdong University, Shandong, 250100, Peop. Rep. China
SO Chinese Journal of Chemistry (1998), 16(2), 171-177
CODEN: CJOCEV; ISSN: 1001-604X
PB Science Press
DT Journal
LA English
AB In order to get good antitumor agents, 49 1-carbamoyl-5-fluorouracils having an arom. ring were synthesized from 5-fluorouracil and isocyanates or amines. Antitumor activity was tested in the L-1210 tumor system, and 5 compds. gave better therapeutic ratios than 5-fluorouracil, tegafur, and HCFU. 1-[(4-Methoxybenzyl)carbamoyl]-5-fluorouracil gave the best result.
IT **208712-96-3P 208712-97-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and antitumor activity of)
RN 208712-96-3 CAPLUS
CN 1(2H)-Pyrimidinecarboxamide, 5-fluoro-3,4-dihydro-2,4-dioxo-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 208712-97-4 CAPLUS
CN 1(2H)-Pyrimidinecarboxamide, 5-fluoro-3,4-dihydro-2,4-dioxo-N-(1,2,3,4-tetrahydro-2-naphthalenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 35 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 1998:180848 CAPLUS
DN 128:243960
TI 8-Hydroxy-7-substituted quinolines as anti-viral agents
IN Vaillancourt, Valerie A.; Romines, Karen R.; Romero, Arthur G.; Tucker, John A.; Strohbach, Joseph W.; Bezencon, Olivier; Thaisrivongs, Suvit; et al.
PA Pharmacia & Upjohn Co., USA; Vaillancourt, Valerie A.; Romines, Karen R.; Romero, Arthur G.; Tucker, John A.; Strohbach, Joseph W.; Bezencon, Olivier; Thaisrivongs, Suvit
SO PCT Int. Appl., 280 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9811073	A1	19980319	WO 1997-US15310	19970905
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9741721	A1	19980402	AU 1997-41721	19970905
	EP 927164	A1	19990707	EP 1997-939690	19970905
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 6310211	B1	20011030	US 1997-924683	19970905
	JP 2002505660	T2	20020219	JP 1998-513685	19970905
	US 6211376	B1	20010403	US 1999-425789	19991022
	US 6252080	B1	20010626	US 1999-425564	19991022
	US 6500842	B1	20021231	US 2001-14780	20011023
PRAI	US 1996-25870P	P	19960910		
	US 1997-50720P	P	19970625		
	US 1997-924683	A3	19970905		
	WO 1997-US15310	W	19970905		

OS MARPAT 128:243960
AB The present invention provides for 8-hydroxy-7-substituted quinoline compds. I (R = alkyl, alkylamino, alkoxyalkyl, etc.; R1 = H, F, Cl, Br, Cf3, etc.; R2 = H, alkyl, OH, arylalkenyl, etc.; R3 = H, OH, CF3, C1-C3alkyl) are prepd. as anti-viral agents. Specifically, these compds. have anti-viral activity against the herpes virus, cytomegalovirus (CMV). Many of these compds. are also active against other herpes viruses, such as the varicella zoster virus, the Epstein-Barr virus, the herpes simplex virus and the human herpes virus type 8 (HHV-8).
IT **205038-70-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 8-hydroxy-7-substituted quinolines as anti-viral agents)
RN 205038-70-6 CAPLUS
CN 7-Quinolinecarboxamide, 8-hydroxy-N-(1,2,3,4-tetrahydro-1-naphthalenyl)-(9CI) (CA INDEX NAME)



p

L4 ANSWER 37 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 1997:640655 CAPLUS
DN 127:307398
TI New piperidinyl- and piperazinyl-substituted 1,2,3,4-tetrahydronaphthalene derivatives useful as 5-HT antagonists
IN Berg, Stefan; Florvall, Lennart; Ross, Svante; Thorberg, Seth-Olov
PA Astra AB, Swed.; Berg, Stefan; Florvall, Lennart; Ross, Svante; Thorberg, Seth-Olov
SO PCT Int. Appl., 137 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9734883	A1	19970925	WO 1997-SE469	19970320
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9702056	A	19970922	ZA 1997-2056	19970310
CA 2247940	AA	19970925	CA 1997-2247940	19970320
AU 9721865	A1	19971010	AU 1997-21865	19970320
AU 709856	B2	19990909		
EP 888319	A1	19990107	EP 1997-914727	19970320
EP 888319	B1	20030129		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1219170	A	19990609	CN 1997-194726	19970320
CN 1073101	B	20011017		
BR 9708093	A	19990727	BR 1997-8093	19970320
JP 2000506883	T2	20000606	JP 1997-533410	19970320
SK 282359	B6	20020107	SK 1998-1188	19970320
AT 231847	E	20030215	AT 1997-914727	19970320
US 6124283	A	20000926	US 1997-836004	19970425
NO 9804385	A	19981123	NO 1998-4385	19980921
US 6410530	B1	20020625	US 2000-653427	20000831
PRAI SE 1996-1110	A	19960322		
WO 1997-SE469	W	19970320		
US 1997-836004	A3	19970425		

OS MARPAT 127:307398
AB New piperidinyl- and piperazinyl-substituted 1,2,3,4-tetrahydronaphthalene derivs. I [X = N or CH; Y = NR2CH2, CH2NR2, NR2CO, CONR2, or NR2SO2; R1 = H, C1-6 alkyl, or C3-6 cycloalkyl; R2 = H or C1-6 alkyl; R3 = C1-6 alkyl, C3-6 cycloalkyl, or (CH2)n-aryl where aryl = Ph or heteroarom. ring contg. 1 or 2 N/O/S atoms and which may be mono- or di-substituted; n = 0-4], as enantiomers, racemates, free bases, or pharmaceutically acceptable salts or hydrates, are disclosed. Also disclosed are pharmaceutical formulations contg. I, use of I in the treatment of disorders mediated by 5-hydroxytryptamine (5-HT), and processes and intermediates for the prepn. of I. The compds. are primarily selective antagonists of the 5-HT1D receptor (no data). A variety of preferred compds., mostly (R)-isomers, are specifically claimed. Synthetic examples (138) include prepn. of both I and their intermediates. For instance, (R)-8-methoxy-2-amino-1,2,3,4-

tetrahydronaphthalene-HCl was converted in 8 steps to (R)-2-amino-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalene, which was condensed with 4-morpholinobenzoic acid using 1,1'-carbonyldiimidazole in DMF to give title compd. II.

IT **197445-50-4P 197445-51-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of piperidinyl- and piperazinyl-substituted tetrahydronaphthalenes as 5-HT1D antagonists)

RN 197445-50-4 CAPLUS
CN 4-Thiazolecarboxamide, 2-phenyl-N-[1,2,3,4-tetrahydro-8-(4-methyl-1-piperazinyl)-2-naphthalenyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 197445-51-5 CAPLUS
CN 4-Thiazolecarboxamide, 2-(4-pyridinyl)-N-[1,2,3,4-tetrahydro-8-(4-methyl-1-piperazinyl)-2-naphthalenyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L4 ANSWER 38 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 1997:425333 CAPLUS
DN 127:39849
TI Hemoregulatory picolinic acid derivatives
IN Bhatnagar, Pradip Kumar; Heerding, Dirk Andries; Hartmann, Michael; Hiebl, Johann; Kremminger, Peter; Rovenszky, Franz
PA Smithkline Beecham Corporation, USA; Nycomed Austria Gmbh; Bhatnagar, Pradip Kumar; Heerding, Dirk Andries; Hartmann, Michael; Hiebl, Johann; Kremminger, Peter; Rovenszky, Franz
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9717958	A1	19970522	WO 1996-US18248	19961112
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 866700	A1	19980930	EP 1996-940439	19961112
	R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
	JP 2000500464	T2	20000118	JP 1997-519063	19961112
	US 6191146	B1	20010220	US 1999-142247	19990401
PRAI	US 1995-6456P	P	19951113		
	WO 1996-US18248	W	19961112		

OS MARPAT 127:39849
AB The present invention relates to novel compds. which have hemoregulatory activities and can be used to stimulate hematopoiesis and for the treatment of viral, fungal and bacterial infectious diseases. An example compd., 1,7-bis(picolinoylamino)-1,2,3,4-tetrahydronaphthalene was prepd. by hydrogenation of 7-nitro-1-tetralone oxime to give 1,7-diamino-1,2,3,4-tetrahydronaphthalene and treatment with picolinic acid.
IT **190962-98-2P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(hemoregulatory picolinic acid derivs.)
RN 190962-98-2 CAPLUS
CN 2-Pyridinecarboxamide, N,N'-(1,2,3,4-tetrahydro-1,7-naphthalenediyl)bis- (9CI) (CA INDEX NAME)



L4 ANSWER 39 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 1997:238316 CAPLUS
DN 126:225227
TI Preparation of quinolones as inhibitors of phosphodiesterase IV and/or tumor necrosis factor (TNF) activity
IN Beasley, Steven Colin; Montana, John Gary; Dyke, Hazel Joan; Haughan, Findlay Alan; Runcie, Karen Ann; Manallack, David Thomas; Buckley, George Martin; Maxey, Robert James; Kendall, Hannah Jayne; Baxter, Andrew Douglas
PA Chiroscience Limited, UK
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9704779	A1	19970213	WO 1996-GB1862	19960802
	W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2225552	AA	19970213	CA 1996-2225552	19960802
	AU 9666263	A1	19970226	AU 1996-66263	19960802
	AU 696390	B2	19980910		
	ZA 9606599	A	19970804	ZA 1996-6599	19960802
	EP 841929	A1	19980520	EP 1996-925905	19960802
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	US 5891878	A	19990406	US 1996-691338	19960802
	JP 11513021	T2	19991109	JP 1996-507373	19960802
PRAI	GB 1995-15811	A	19950802		
	GB 1995-26377	A	19951222		
	GB 1996-5868	A	19960320		
	GB 1996-11898	A	19960607		
	WO 1996-GB1862	W	19960802		

OS MARPAT 126:225227
AB The title compds. [I; R1 = C1-6 alkyl, C1-6 alkylcycloalkyl, etc.; R3 = Ph, pyridyl, thienyl, etc.; Y = O, S; R4-R7 = H, halo, C1-6 alkoxy, etc.; n = 0-3], useful as antiasthmatics, antiallergics, antiinflammatories, antiarthritics, and antifungal agents, were prepd. Thus, treatment of 1-ethyl-4-hydroxy-6-(trifluoromethyl)quinoline-3-carboxylate with Et3N and isopropenyl chloroformate in CH2Cl2 followed by addn. of 4-(2-aminoethyl)pyridine afforded I [R1 = Et; R3 = 4-pyridyl; R5 = CF3, R4, R6, R7 = H; Y = O; n = 2],. Compds. I are effective at 0.01-0.5 mg/kg/day.
IT **188202-59-7P 188202-62-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of quinolones as inhibitors of phosphodiesterase IV and/or tumor necrosis factor (TNF) activity)
RN 188202-59-7 CAPLUS
CN 1,3-Dioxolo[4,5-g]quinoline-7-carboxamide, 5-ethyl-5,8-dihydro-8-oxo-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 188202-62-2 CAPLUS
CN 1,3-Dioxolo[4,5-g]quinoline-7-carboxamide, 5-ethyl-5,8-dihydro-8-oxo-N-(1,2,3,4-tetrahydro-2-naphthalenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 40 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 1997:238313 CAPLUS
DN 126:225310
TI Preparation of 1-alkyl-substituted-quinolone-3-carboxamides as inhibitors of phosphodiesterase IV and/or tumor necrosis factor (TNF) activity
IN Beasley, Steven Colin; Montana, John Gary; Dyke, Hazel Joan; Haughan, Findlay Alan; Runcie, Karen Ann; Manallack, David Thomas; Buckley, George Martin; Maxey, Robert James; Kendall, Hannah Jayne; Baxter, Andrew Douglas
PA Chiroscience Limited, UK
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9704775	A1	19970213	WO 1996-GB1866	19960731
	W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2225555	AA	19970213	CA 1996-2225555	19960731
	AU 9666266	A1	19970226	AU 1996-66266	19960731
	AU 695132	B2	19980806		
	EP 841927	A1	19980520	EP 1996-925909	19960731
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 11510156	T2	19990907	JP 1996-507375	19960731
	ZA 9606600	A	19970804	ZA 1996-6600	19960802
	US 5753666	A	19980519	US 1996-691339	19960802
PRAI	GB 1995-15812	A	19950802		
	GB 1995-23679	A	19951120		
	GB 1996-5865	A	19960320		
	GB 1996-11898	A	19960607		
	WO 1996-GB1866	W	19960731		

OS MARPAT 126:225310
AB The title compds. [I; R1 = C1-6 alkyl, C1-6 alkylcycloalkyl, etc.; R3 = Ph, pyridyl, thienyl, etc.; Y = O, S; X = C, N; Q = C, N (at least one of X and Q = N); R4-R7 = H, halo, C1-6 alkoxy, etc.], useful as antiasthmatics, antiallergics, antiinflammatories, antiarthritics, antifungal agents, and for treating pathol. condition assocd. with eosinophil accumulation or an function of the eosinophil, were prepd. Thus, treatment of nalidixic acid with Et3N and isopropenyl chloroformate in CH2Cl2 followed by addn. of 4-(2-aminoethyl)pyridine afforded I [R1 = Et; R3 = 4-pyridyl; Y = O; X = C; Q = N; R6 = Me; R4, R5, R7 = H; n = 2]. Compds. I are effective at 0.01-0.5 mg/kg/day.
IT **188203-02-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of 1-alkyl-substituted-quinolone-3-carboxamides as inhibitors of phosphodiesterase IV and/or tumor necrosis factor (TNF) activity)
RN 188203-02-3 CAPLUS
CN Pyrido[2,3-d]pyrimidine-6-carboxamide, 8-ethyl-5,8-dihydro-5-oxo-2-(1-pyrrolidinyl)-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX

NAME)



IT **188203-03-4P 188203-12-5P 188203-16-9P 188203-17-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 1-alkyl-substituted-quinolone-3-carboxamides as inhibitors of phosphodiesterase IV and/or tumor necrosis factor (TNF) activity)

RN 188203-03-4 CAPLUS

CN Pyrido[2,3-d]pyrimidine-6-carboxamide, 8-ethyl-5,8-dihydro-5-oxo-2-(1-pyrrolidinyl)-N-(1,2,3,4-tetrahydro-1-naphthalenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 188203-12-5 CAPLUS

CN Pyrido[2,3-d]pyrimidine-6-carboxamide, 8-ethyl-5,8-dihydro-5-oxo-2-(1-pyrrolidinyl)-N-(1,2,3,4-tetrahydro-2-naphthalenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 188203-16-9 CAPLUS
CN Pyrido[2,3-d]pyrimidine-6-carboxamide, N-[6-(acetylamino)-1,2,3,4-tetrahydro-1-naphthalenyl]-8-ethyl-5,8-dihydro-5-oxo-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 188203-17-0 CAPLUS
CN Pyrido[2,3-d]pyrimidine-6-carboxamide, N-[6-(acetylamino)-1,2,3,4-tetrahydro-1-naphthalenyl]-8-ethyl-5,8-dihydro-5-oxo-2-(1-pyrrolidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L4 ANSWER 42 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 1995:890010 CAPLUS
DN 123:313949
TI Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations thereof
IN Greenwood, Beverley; Helton, David R.; Howbert, J. Jeffry; Mitan, Steven J.; Raşmussen, Kurt
PA Lilly, Eli, and Co., USA
SO U.S., 37 pp. Cont.-in-part of U.S. 5,300,519.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5399565	A	19950321	US 1993-151608	19931112
	US 5300514	A	19940405	US 1993-33737	19930318
	US 5643926	A	19970701	US 1994-183465	19940119
PRAI	US 1990-553489		19900717		
	US 1991-737624		19910730		
	US 1992-982257		19921125		
	US 1993-33737		19930318		

OS MARPAT 123:313949
AB Novel substituted pyrazolidinones I or II [R and R1 are independently hydrogen, C1-C6 alkyl, Ph, benzyl, naphthyl, pyridyl or substituted Ph having 1, 2, or 3 substituents selected from the group consisting of, e.g., C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio; R2 is hydrogen, C1-C6 alkyl, carboxymethyl, C1-C4 alkoxycarbonylmethyl or a group of the formula CO(A)tY wherein t is 1 or 0; A is CH2, O, NH or N(C1-C6 alkyl); and Y is Ph or substituted Ph as defined above; R4 is C1-C6 alkyl, carboxymethyl, or C1-C4 alkoxycarbonylmethyl; R3 is hydrogen or a group of the formula III or C(:B)(Q)nR5 wherein B is O or S; X is selected from the Ph substituents defined above; m is 0, 1 or 2; n is 0 or 1; Q is NH, N(C1-C6 alkyl), S, or O; and R5 is a group of the formula [CH(R6)]q(CH2)rR7 wherein R6 is hydrogen or C1-C6 alkyl; q is 0 or 1; r is 0, 1 or 2; and R7 is hydrogen, C1-C8 alkyl, C3-C8 cycloalkyl, pentafluorophenyl, pyridyl, tetrahydro-naphthyl, indolyl, quinolinyl, Ph, naphthyl, or Ph or naphthyl substituted with 1, 2 or 3 substituents] have been found to exhibit significant binding to cholecystokinin (CCK) receptors and gastrin receptors in the brain and/or peripheral sites such as the pancreas, stomach, and ileum. The pyrazolidinones are CCK and gastrin receptor antagonists and find therapeutic application in the treatment of gastrointestinal disorders, central nervous system disorders and for appetite regulation in warm-blood vertebrates. Pharmaceutical formulations for such indications are described. Thus, e.g., reaction of 4,5-diphenyl-3-pyrazolidinone with 4-chloro-3-trifluoromethylphenyl isocyanate afforded 85% 1-[(4-chloro-3-trifluoromethylphenyl)aminocarbonyl]-4,5-diphenyl-3-pyrazolidinone I (R3 = 4-Cl-3-CF3C6H3NHCO, R = R1 = Ph, R2 = H) which was evaluated for CCK and gastrin receptor binding: IC50 (.mu.M) for CCK receptor binding in brain and pancreas = 0.022 and 0.19, resp.; IC50 (.mu.M) for gastrin receptor binding = 0.15.
IT **169671-82-3P 169672-82-6P**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(prepn. of pyrazolidinones as CCK and gastrin receptor antagonists)
RN 169671-82-3 CAPLUS

CN 1-Pyrazolidinecarboxamide, 3-oxo-4,5-diphenyl-N-(1,2,3,4-tetrahydro-2-naphthalenyl)-, [1(R*),4.alpha.,5.beta.]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 169672-82-6 CAPLUS

CN 1-Pyrazolidinecarboxamide, 3-oxo-4,5-diphenyl-N-(1,2,3,4-tetrahydro-2-naphthalenyl)-, [1(S*),4.alpha.,5.beta.]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 44 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 1995:428717 CAPLUS
DN 122:188168
TI Preparation of peptides as .delta. opioid antagonists.
IN Schiller, Peter
PA Aktiebolaget Astra, Swed.
SO PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9415959	A1	19940721	WO 1993-SE1090	19931220
	W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2152380	AA	19940721	CA 1993-2152380	19931220
	AU 9458448	A1	19940815	AU 1994-58448	19931220
	AU 681372	B2	19970828		
	EP 678099	A1	19951025	EP 1994-904365	19931220
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	HU 72597	A2	19960528	HU 1995-2041	19931220
	JP 08505386	T2	19960611	JP 1993-515914	19931220
	US 5602099	A	19970211	US 1994-176938	19940104
	ZA 9400055	A	19940705	ZA 1994-55	19940105
	CN 1096515	A	19941221	CN 1994-100129	19940105
	LV 10962	B	19970420	LV 1995-197	19950629
	FI 9503302	A	19950704	FI 1995-3302	19950704
	NO 9502650	A	19950830	NO 1995-2650	19950704
PRAI	SE 1993-12		19930105		
	WO 1993-SE1090		19931220		

OS MARPAT 122:188168
AB Title compds. [I; R1 = H, Me(CH2)n, PhCH2CH2, cyclopropylmethyl, allyl, H-Arg; R2 = H, Me(CH2)n, cyclopropylmethyl, allyl, etc.; n = 0-12; R3-R6 = H, or R4, R5 both = H and R3, R6 both = lower alkyl, or R3, R5, R6all = H and R4 = F, Cl, Br, OH, NH2, NO2; R7 = CO, CH2; R8= H, lower alkyl; R9= Q1-Q7; m = 0-2; R10 = H, F, Cl, Br, iodo; R11 = OH, NH2, Q8, Q9; R12 = H, NO2, F, Cl, Br, iodo; m = 0-2; R13, R14 = CO2H, CONH2, CH2OH, amino acid or peptide segment; with the exceptions of compds. where R1, R2, R3, R4, R5, R6, R8 all = H, R7 = CO, R9 = PhCH2CH, and R11 = Phe-OH, Phe-NH2, OH, NH2], were prepd. Thus, H-Tyr-Tic-Hfe-Phe-OH (Tic = 1,2,3,4-tetrahydroisoquinoline-3-carboxylate; Hfe = homophenylalanyl), was prepd. by solid phase synthesis. I antagonized [Leu5] enkephalin in mouse vas deferens with Ke = 0.169-43.9 nM.
IT **161669-10-9**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptides as .delta. opioid antagonists)
RN 161669-10-9 CAPLUS
CN L-Phenylalanine, L-tyrosyl-L-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-1,2,3,4-tetrahydro-2-amino-2-naphthalenecarbonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10.

L4 ANSWER 45 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 1994:8500 CAPLUS
DN 120:8500
TI Syntheses and photophysical properties of some 5(2)-aryl-2(5)-(4-pyridyl)oxazoles and related oxadiazoles and furans
AU Kauffman, Joel M.; Litak, Peter T.; Adams, Jeffrey K.; Henry, Ronald A.; Hollins, Richard A.
CS Dep. Chem., Philadelphia Coll. Pharm. Sci., Philadelphia, PA, 19104-4495, USA
SO Journal of Heterocyclic Chemistry (1992), 29(5), 1245-73
CODEN: JHTCAD; ISSN: 0022-152X
DT Journal
LA English
AB A no. of 5-aryl-2-(4-pyridyl)oxazoles, a 2-aryl-5-(4-pyridyl)oxazole, the related oxadiazole and furan, several 2-(4-pyridyl)cycloalkano[d]oxazoles, and many of their quaternary salts were prepd. Thus, 4-RC6H4CH2CR1:NOH (R = H, F, R1 = Me; R = H, R1 = Ph, CH2Ph) reacted with isonicotinoyl chloride hydrochloride to give phenylpyridyloxazoles I. No single std. synthesis was effective for prepn. of more than a few of the 25 free bases described; methods often unique to a base were employed. Minor variations in structure sometimes produced large differences in absorption and emission wavelengths, as well as in the magnitude of the extinction coeff. The salts are of interest as laser dyes, scintillation fluors, biol. stains, and shifters for luminescent solar concentrators.
IT **129008-10-2P 129008-11-3P 151457-95-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and intramol. cyclocondensation of)
RN 129008-10-2 CAPLUS
CN 4-Pyridinecarboxamide, N-(1,2,3,4-tetrahydro-1-oxo-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 129008-11-3 CAPLUS
CN 4-Pyridinecarboxamide, N-(1,2,3,4-tetrahydro-6-methoxy-1-oxo-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 151457-95-3 CAPLUS
CN 4-Pyridinecarboxamide, N-(6-fluoro-1,2,3,4-tetrahydro-1-oxo-2-naphthalenyl)- (9CI) (CA INDEX NAME)


O
O
NH
C
N
F

L4 ANSWER 46 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 1993:560066 CAPLUS
DN 119:160066
TI 2,2-Dialkylnaphthalen-1-ones as new potassium channel activators
AU Almansa, Carmen; Gomez, Luis A.; Cavalcanti, Fernando L.; Rodriguez, Ricardo; Carceller, Elena; Bartroli, Javier; Garcia-Rafanell, Julian; Forn, Javier
CS Res. Cent., J. Uriach y Cia.S.A., Barcelona, 08026, Spain
SO Journal of Medicinal Chemistry (1993), 36(15), 2121-33
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
AB A new series of 2,2-dialkylnaphthalen-1-one potassium channel activators has been prepd., and their in vitro relaxant activities in isolated rat portal vein and guinea pig tracheal spirals as well as their oral antihypertensive effect in spontaneously hypertensive rats have been evaluated. The group of 1,2-dihydro-4-(1,2-dihydro-2-oxo-1-pyridyl)-2,2-dimethylnaphthalen-1-ones with an electron-withdrawing substituent at the 6-position contain the most active compds. and 1,2-dihydro-4-(1,2-dihydro-2-oxo-1-pyridyl)-2,2-dimethyl-1-oxonaphthalene-6-carbonitrile, (UR-8225) (I), has been selected for further pharmacol. development.
IT **149915-53-7P 149915-54-8P 149915-55-9P**
149915-56-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and potassium channel activator activity of)
RN 149915-53-7 CAPLUS
CN 2-Pyridinecarboxamide, N-(7-cyano-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 149915-54-8 CAPLUS
CN 3-Pyridinecarboxamide, N-(7-cyano-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 149915-55-9 CAPLUS
CN 4-Pyridinecarboxamide, N-(7-cyano-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 149915-56-0 CAPLUS

L4 ANSWER 47 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 1993:495539 CAPLUS
DN 119:95539
TI Heterocyclyl group-substituted tetralones having antihypertensive and bronochodilating activity
IN Almansa, Carmen; Gonzalez, M. Concepcion; Torres, M. Carmen; Carceller, Elena; Bartroli, Javier
PA Uriach, J., e Cia. S.A., Spain
SO Eur. Pat. Appl., 39 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 525768	A1	19930203	EP 1992-113007	19920730
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE				
ES 2033581	A1	19930316	ES 1991-1777	19910730
ES 2033581	B1	19931216		
ES 2041212	A1	19931101	ES 1992-333	19920217
ES 2041212	B1	19940516		
CA 2074864	AA	19930131	CA 1992-2074864	19920729
PRAI ES 1991-1777		19910730		
ES 1992-333		19920217		

OS MARPAT 119:95539
AB The title compds. I [R1, R2 = H, OH, CHO, CO2H, NO2, NH2CN, halogen, OCF3, alkoxy, C.tplbond.CH, (un)substituted alkylcarbonyl, arylsulfinyl, alkylsulfinyl, arylsulfenyl, alkyl, alkylsulfonylamino, aminosulfinyl, aminosulfonyl, etc.; R3 = H, alkyl; R4 = alkyl; R5 = OH, acetoxy, formyloxy; R6 = H, olefinic bond with R5; Z = O, NR8; R3R4 = C2-5 methylene chain; if Z = O, then R7 = R9 where R9 = C3-6 cycloalkyl, C3-6 cycloalkenyl, Ph, heteroaryl (all optionally substituted by 1-2 halogen atoms and/or 1-2 C1-6 alkyl, C1-6 alkoxy, arylmethyloxy, etc., but when Z = NR8, then R7 = R9, C(:X)R10; R10 = H, (un)substituted C1-6 alkyl, C2-6 alkenyl, C3-6 cycloalkyl, (un)substituted Ph, (un)substituted heteroaryl; X = O, S, NCN], useful as antihypertensive and bronchodilating agents, are prepd. Thus, 3,4-epoxy-2,2-dimethyl-1-oxo-1,2,3,4-tetrahydronaphthalene-6-carbonitrile reacted with 3,6-dihydroxypyridazine to give trans-2,2-dimethyl-3-hydroxy-4-(6-hydroxy-3-pyridazinyloxy)-1-oxo-1,2,3,4-tetrahydrononaphthalene-6-carbonitrile (II) in 65% yield. In spontaneously hypertense rats at 1 mg/kg, II lowered arterial blood pressure 116 mm Hg, and at 8.8 .mu.M inhibited 50% noradrenaline-induced contraction in portal vein isolated from rat.
IT **148925-60-4P 148925-63-7P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and antihypertensive and bronchodilating activity of)
RN 148925-60-4 CAPLUS
CN 3-Furancarboxamide, N-(7-cyano-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 148925-63-7 CAPLUS
CN 2-Pyridinecarboxamide, N-[2-(acetyloxy)-7-cyano-1,2,3,4-tetrahydro-3,3-dimethyl-4-oxo-1-naphthalenyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 48 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 1992:530937 CAPLUS
DN 117:130937
TI Derivatives of 1,2,3,4-tetrahydronaphthylamine endowed with nootropic activity and pharmaceutical compositions containing same
IN Giannessi, Fabio; Ghirardi, Orlando; Misiti, Domenico; Tinti, Maria Ornella; Cozzolino, Roberto
PA Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Italy
SO Eur. Pat. Appl., 15 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 493346	A2	19920701	EP 1991-830574	19911219
	EP 493346	A3	19920826		
	EP 493346	B1	19950614		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
	US 5192759	A	19930309	US 1991-809874	19911218
	ES 2073725	T3	19950816	ES 1991-830574	19911219
	JP 04275264	A2	19920930	JP 1991-338442	19911220
PRAI	IT 1990-48605		19901221		

OS MARPAT 117:130937
AB The title compds. I [R = H, OMe; NR1R2 is at the 1- or 2-position; R1 = H; R2 = L-prolyl, optionally substituted, L-pyroglutamyl, (pyrrolidin-2-on-1-yl)acetyl, 3-carboxy-2-hydroxypropyl; NR1R2 = Q (n = 1, 2, 3 and R3 = H, OH)] were prepd. as nootropic agents. E.g., reaction of Z-L-proline and 1,2,3,4-tetrahydro-6,7-dimethoxy-2-naphthylamine in MeCN in the presence of EEDQ gave 85% product, which was hydrogenated in MeOH with 10% Pd/C at 40 psi for 2 h to give 71% N-(L-prolyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-naphthylamine (II). Of the compds. prepd. and tested, only II showed antiamnesic activity, without toxicity, in scopolamine- and electroconvulsive shock-induced amnesia.
IT **143277-73-0P 143277-75-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 143277-73-0 CAPLUS
CN 2-Pyrrolidinecarboxamide, 5-oxo-N-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 143277-75-2 CAPLUS
CN 2-Pyrrolidinecarboxamide, 5-oxo-N-(1,2,3,4-tetrahydro-6,7-dimethoxy-1-naphthalenyl)- (9CI) (CA INDEX NAME)


O
NH
C
O
NH
OMe
OMe

L4 ANSWER 49 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 1992:194306 CAPLUS
DN 116:194306
TI Preparation of pyrazolidin-3-ones as cholecystokinin and gastrin antagonists
IN Brown, Raymond Frank; Howbert, James Jeffry; Lobb, Karen Lynn; Neel, David Andrew; Reel, Jon Kevin
PA Lilly, Eli, and Co., USA
SO Eur. Pat. Appl., 44 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 467614	A1	19920122	EP 1991-306374	19910715
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 2046672	AA	19920118	CA 1991-2046672	19910710
ZA 9105372	A	19930331	ZA 1991-5372	19910710
IL 98785	A1	19951127	IL 1991-98785	19910710
AU 9180409	A1	19920123	AU 1991-80409	19910712
AU 644190	B2	19931202		
NO 9102772	A	19920120	NO 1991-2772	19910715
HU 58296	A2	19920228	HU 1991-2376	19910715
FI 9103431	A	19920118	FI 1991-3431	19910716
CN 1058209	A	19920129	CN 1991-104911	19910716
CN 1032000	B	19960612		
BR 9103042	A	19920428	BR 1991-3042	19910716
JP 04230367	A2	19920819	JP 1991-175054	19910716
RU 2076100	C1	19970327	RU 1991-5001032	19910716
AU 9455293	A1	19940428	AU 1994-55293	19940221

PRAI US 1990-553489 19900717
OS MARPAT 116:194306
AB Title compds. (I, II; R, R1 = H, alkyl, Ph, PhCH2, naphthyl, pyridyl, substituted Ph; R2 = H, alkyl, carboxymethyl, alkoxycarbonylmethyl, acyl; R3 = H, Q1, etc.; R4 = alkyl, carboxymethyl, alkoxycarbonylmethyl; X = alkyl, alkoxy, alkylthio, halo, CF3, Ph, PhO, cyano, NO2, amino, etc.; Y = O, S; m = 0-2), were prepd. Thus, 3-trifluoromethylbenzoyl chloride and 4,5-diphenyl-3-pyrazolidinone were stirred 2.3 h in THF to give title compd. III. III at 10 .mu.M gave 77% inhibition of 125-I cholecystokinin-8 binding to mouse brain prepns.
IT **140688-03-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as cholecystokinin and gastrin antagonist)
RN 140688-03-5 CAPLUS
CN 1-Pyrazolidinecarboxamide, 3-oxo-4,5-diphenyl-N-(1,2,3,4-tetrahydro-2-naphthalenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 50 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 1991:471632 CAPLUS
DN 115:71632
TI Preparation of new N-aryl and N-heteroaryl amide and -urea derivatives as inhibitors of acyl coenzyme A:cholesterol acyltransferase
IN McCarthy, Peter A.; Walker, Frederick J.; Truong, Thien; Hamanaka, Ernest S.; Chang, George
PA Pfizer Inc., USA
SO Eur. Pat. Appl., 85 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 418071	A2	19910320	EP 1990-310009	19900913
	EP 418071	A3	19920325		
	EP 418071	B1	19950426		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	WO 9104027	A1	19910404	WO 1989-US4033	19890915
	W: FI, HU, NO, RO, SU, US				
	IL 95610	A1	19941229	IL 1990-95610	19900907
	DD 298092	A5	19920206	DD 1990-343971	19900912
	CA 2025301	AA	19910316	CA 1990-2025301	19900913
	CA 2025301	C	20011016		
	EP 609960	A1	19940810	EP 1994-200437	19900913
	EP 609960	B1	19990303		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AT 121730	E	19950515	AT 1990-310009	19900913
	ES 2071033	T3	19950616	ES 1990-310009	19900913
	AT 177082	E	19990315	AT 1994-200437	19900913
	ES 2127878	T3	19990501	ES 1994-200437	19900913
	NO 9004022	A	19910318	NO 1990-4022	19900914
	CN 1050183	A	19910327	CN 1990-108294	19900914
	HU 54625	A2	19910328	HU 1990-5991	19900914
	AU 9062553	A1	19910418	AU 1990-62553	19900914
	AU 652345	B2	19940825		
	JP 03120243	A2	19910522	JP 1990-245969	19900914
	JP 08025974	B4	19960313		
	ZA 9007346	A	19920527	ZA 1990-7346	19900914
	PL 165370	B1	19941230	PL 1990-286899	19900914
	PL 165357	B1	19941230	PL 1990-291470	19900914
	HU 70027	A2	19950928	HU 1993-2945	19900914
PRAI	WO 1989-US4033	A	19890915		
	EP 1990-310009	A3	19900913		

OS MARPAT 115:71632
AB Approx. 250 title amides and ureas R1NHCOQ [Q = CR2R3R4, NR5R6; R1 = (substituted) pyridyl, pyrimidinyl, quinolinyl, pyridoimidazolyl, etc., substituted Ph; R2-R4 = H, alkyl, hydrocarbyl, XR7, phenylalkyl, cycloalkyl; or R3R3 forms cycloalkyl, cycloalkenyl, bicycloalkyl, etc.; R5, R6 = alkyl, phenylalkyl, alkylphenylalkyl; R7 = alkyl, cycloalkyl, phenylalkyl, thiazolyl, pyridyl, etc.; X = O, S, SO, SO2, NH, etc.; numerous provisos] were prepd. as hypolipidemics and antiatherosclerotics (no data). For example, 2-(hexylthio)decanoic acid was refluxed with SOCl2 in C6H6 to give the acid chloride, which was added to 5-amino-4,6-bis(methylthio)-2-methylpyrimidine in CH2Cl2 followed by refluxing and purifn. to give 72.4% title amide I.
IT **134991-63-2P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as hypolipidemic)

RN 134991-63-2 CAPLUS

CN 5-Quinolinecarboxamide, 6-(methylthio)-N-[1,2,3,4-tetrahydro-3-nonyl-2-naphthalenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 51 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 1990:532164 CAPLUS
DN 113:132164
TI Preparation of 2-(4-N-methylpyridinium)-4,5-dihydronaphtho[2,1-d]-1,3-oxazole p-toluenesulfonate and its analog as rigidized oxazole laser dyes
IN Hall, John H.; Henry, Ronald A.; Hollins, Richard A.
PA United States Dept. of the Navy, USA
SO Statutory Invent. Regist., 5 pp.
CODEN: SRXXEV
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 753	H1	19900306	US 1989-297891	19890117
PRAI US 1989-297891		19890117		

OS MARPAT 113:132164
AB The title compds. (I; R = H, MeO), rigidized by an ethylene bridge between the 4-position of the 1,3-oxazole and the o-position of the arom. ring, were prepd. by a procedure comprising: (1) conversion of 1-tetralones to 2-oximes by BuONO, (2) acid catalytic redn. to 2-amino-1-tetralone salts, N-acylation by isonicotinoyl chloride, and (3) a Robinson-Gabriel modified ring closure of the resulting amide by dehydration with POCl3. 1-Tetralone was added dropwise over 10 min to a soln. of tert-BuOK in tert-BuOH and Et2O, followed by BuONO over 1 h. The product (59%) was hydrogenated over 1 h 20 min at 50 psi in the presence of Pd/BaSO4 and aq. HCl in MeOH, and the resulting 2-amino-1-tetralone hydrochloride (50%) reacted in pyridine over 2 h with isonicotinic acid chloride. The obtained isonicotinamide (50%) was refluxed 19 h in POCl3 to give 72% oxazole II which, after refluxing for 18 h with 4-MeOC6H4SO3Me in CH2Cl2, gave 91% title compd. I (R = H). The fluorescence wavelengths of the latter in EtOH were at 522 and 308 nm; that of II was at 434 nm.
IT **129008-10-2P 129008-11-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and cyclodehydration of, by phosphorus oxychloride, in prepn. of rigidized laser dye)
RN 129008-10-2 CAPLUS
CN 4-Pyridinecarboxamide, N-(1,2,3,4-tetrahydro-1-oxo-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 129008-11-3 CAPLUS
CN 4-Pyridinecarboxamide, N-(1,2,3,4-tetrahydro-6-methoxy-1-oxo-2-naphthalenyl)- (9CI) (CA INDEX NAME)


MeO
O
NH
C
O
N

L4 ANSWER 53 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 1988:604933 CAPLUS
DN 109:204933
TI Preparation of pyridine-2,4- and -2,5-dicarboxylic acid amides as collagen formation-inhibiting drugs
IN Bickel, Martin; Brocks, Dietrich; Burghard, Harald; Guenzler, Volkmar; Henke, Stephan; Hanauske-Abel, Hartmut M.; Mohr, Juergen; Tschank, Georg
PA Hoechst A.-G., Fed. Rep. Ger.
SO Ger. Offen., 9 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3703959	A1	19880818	DE 1987-3703959	19870210
	FI 8800556	A	19880811	FI 1988-556	19880208
	FI 91525	B	19940331		
	FI 91525	C	19940711		
	EP 278453	A2	19880817	EP 1988-101792	19880208
	EP 278453	A3	19891025		
	EP 278453	B1	19941228		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	ES 2067448	T3	19950401	ES 1988-101792	19880208
	AU 8811452	A1	19880811	AU 1988-11452	19880209
	AU 599746	B2	19900726		
	DK 8800659	A	19880811	DK 1988-659	19880209
	DK 167804	B1	19931220		
	NO 8800558	A	19880811	NO 1988-558	19880209
	NO 174420	B	19940124		
	NO 174420	C	19940504		
	JP 63216873	A2	19880909	JP 1988-26723	19880209
	JP 06041450	B4	19940601		
	ZA 8800896	A	19880928	ZA 1988-896	19880209
	CA 1334972	A1	19950328	CA 1988-558496	19880209
	HU 47250	A2	19890228	HU 1988-609	19880210
	HU 205905	B	19920728		
	US 5037839	A	19910806	US 1989-434402	19891113
	US 5153208	A	19921006	US 1991-726727	19910701
	US 5512586	A	19960430	US 1995-367770	19950103
	US 5672614	A	19970930	US 1995-482815	19950607
PRAI	DE 1987-3703959		19870210		
	US 1988-153087		19880208		
	US 1989-434309		19891113		
	US 1991-726727		19910701		
	US 1992-906676		19920630		
	US 1993-66922		19930525		
	US 1995-367770		19950103		

OS CASREACT 109:204933; MARPAT 109:204933
AB The title drugs I [R1 = (un)substituted alkyl, indolyl or Ph; R2 = H, R1; NR1R2 = hetero = cyclyl] are prepd. by reaction I (NR1R2=Y; Y = halo, OH) with HNR1R2. Pyridine-2,5--dicarboxylic acid in CH2Cl2 was treated with SOCl2 in DMF, and the mixt. was refluxed for 3 h, followed by treatment with 3-isopropoxypropylamine in CH2Cl2, at -30 to -20.degree., to give pyridine-2,5-dicarboxylic acid N,N'-di(3-isopropoxypropyl)amide (II). Two 25 mg does of II increased in the rat liver, in vivo, the levels of hydroxyproline, procollagen II peptide, 7S-collagen and type-IV collagen NC1.

IT **117517-24-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as collagen formation -inhibiting drug)
RN 117517-24-5 CAPLUS
CN 2,5-Pyridinedicarboxamide, N,N'-bis(1,2,3,4-tetrahydro-1-naphthalenyl)-(9CI) (CA INDEX NAME)



L4 ANSWER 54 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 1988:221420 CAPLUS
DN 108:221420
TI Preparation of substituted amino-5,6,7,8-tetrahydronaphthyloxyacetic acid derivatives as antithrombotics, antiischemics, and antiatherosclerotics
IN Niewoehner, Ulrich; Hoever, Franz Peter; Junge, Bodo; Perzborn, Elisabeth; Seuter, Friedel; Fiedler, Volker Bernd
PA Bayer A.-G., Fed. Rep. Ger.
SO Ger. Offen., 18 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3623941	A1	19880128	DE 1986-3623941	19860716
	US 4868331	A	19890919	US 1987-68002	19870629
	NO 8702784	A	19880118	NO 1987-2784	19870702
	EP 253257	A2	19880120	EP 1987-109694	19870706
	EP 253257	A3	19881130		
	EP 253257	B1	19901114		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE				
	AT 58372	E	19901115	AT 1987-109694	19870706
	FI 8703112	A	19880117	FI 1987-3112	19870714
	DK 8703682	A	19880117	DK 1987-3682	19870715
	AU 8775696	A1	19880121	AU 1987-75696	19870715
	AU 591999	B2	19891221		
	JP 63023847	A2	19880201	JP 1987-175000	19870715
	ZA 8705168	A	19880330	ZA 1987-5168	19870715
	CN 87104970	A	19880203	CN 1987-104970	19870716
	HU 45489	A2	19880728	HU 1987-3253	19870716
	HU 198442	B	19891030		
	US 4921998	A	19900501	US 1989-352073	19890515
PRAI	DE 1986-3623941		19860716		
	US 1987-68002		19870629		
	EP 1987-109694		19870706		

OS CASREACT 108:221420; MARPAT 108:221420
AB Title compds. I [R1 = R3CO, SO2R4; R3 = (substituted) aryl, heteroaryl, aralkyl; R4 = (substituted) aryl; R2 = OH, alkoxy, phenoxy, amino] are prepd. as antiischemics, antithrombotics and antiatherosclerotics. Heating a mixt. of 10 mmol 6-amino-5,6,7,8-tetrahydronaphth-1-yloxyacetic acid and 20 mmol PhSO3H for 2 h at 80.degree. in the presence of NaOH gave 63 g I (R1 = SO2Ph at 5-position, R2 = OH at 1-position) which gave in vitro platelet aggregation inhibition at 0.1-0.3 mg/L.
IT **114665-40-6P 114665-45-1P 114665-48-4P**
114665-71-3P 114665-80-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as antithrombotic)
RN 114665-40-6 CAPLUS
CN Acetic acid, [[5,6,7,8-tetrahydro-5-[(3-pyridinylcarbonyl)amino]-1-naphthalenyl]oxy]- (9CI) (CA INDEX NAME)



RN 114665-45-1 CAPLUS
CN Acetic acid, [[5,6,7,8-tetrahydro-6-[(3-pyridinylcarbonyl)amino]-1-naphthalenyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 114665-48-4 CAPLUS
CN Acetic acid, [[5,6,7,8-tetrahydro-6-[(3-pyridinylcarbonyl)amino]-2-naphthalenyl]oxy]- (9CI) (CA INDEX NAME)



RN 114665-71-3 CAPLUS
CN Acetic acid, [[5,6,7,8-tetrahydro-5-[(3-pyridinylcarbonyl)amino]-1-naphthalenyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 114665-80-4 CAPLUS
CN Acetic acid, [[5,6,7,8-tetrahydro-6-[(3-pyridinylcarbonyl)amino]-2-naphthalenyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)



IT **114665-57-5P 114665-62-2P 114665-64-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as antithrombotic intermediate)
RN 114665-57-5 CAPLUS
CN 3-Pyridinecarboxamide, N-(1,2,3,4-tetrahydro-5-hydroxy-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 114665-62-2 CAPLUS
CN 3-Pyridinecarboxamide, N-(1,2,3,4-tetrahydro-5-hydroxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 114665-64-4 CAPLUS
CN 3-Pyridinecarboxamide, N-(1,2,3,4-tetrahydro-6-hydroxy-2-naphthalenyl)-
(9CI) (CA INDEX NAME)



L4 ANSWER 56 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 1973:405361 CAPLUS
DN 79:5361
TI Pyrimidinylbenzenesulfonamides
IN Huebner, Manfred; Heerdt, Ruth; Schmidt, Felix Helmut; Thiel, Max; Weyer, Rudi
PA Boehringer Mannheim G.m.b.H.
SO Ger. Offen., 22 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2152230	A1	19730426	DE 1971-2152230	19711020
	US 3849417	A	19741119	US 1972-296744	19721011
	CS 161959	P	19750610	CS 1972-427	19721013
	CS 161961	P	19750610	CS 1972-429	19721013
	CS 161958	P	19750610	CS 1972-6936	19721013
	CS 161960	P	19750610	CS 1974-428	19721013
	GB 1346705	A	19740213	GB 1972-47608	19721016
	IL 40585	A1	19760430	IL 1972-40585	19721016
	NL 7214010	A	19730425	NL 1972-14010	19721017
	AU 7247858	A1	19731011	AU 1972-47858	19721017
	DK 130297	B	19750203	DK 1972-5124	19721017
	CH 578558	A	19760813	CH 1972-15137	19721017
	CH 578560	A	19760813	CH 1976-2724	19721017
	CH 578559	A	19760813	CH 1976-2722	19721017
	CH 591476	A	19770915	CH 1976-2723	19721017
	FR 2157878	A1	19730608	FR 1972-36850	19721018
	ZA 7207443	A	19730829	ZA 1972-7443	19721018
	DD 101153	C	19731020	DD 1972-166307	19721018
	AT 319954	B	19750127	AT 1972-8965	19721019
	AT 319958	B	19750127	AT 1974-306	19721019
	AT 319959	B	19750127	AT 1974-309	19721019
	AT 319957	B	19750127	AT 1974-305	19721019
	ES 407775	A1	19751101	ES 1972-407775	19721019
	PL 83610	P	19751231	PL 1972-158370	19721019
	CA 985682	A1	19760316	CA 1972-154566	19721019
	SU 556726	D	19770430	SU 1972-1839306	19721019
	PL 92393	P	19770430	PL 1972-175422	19721019
	PL 92394	P	19770430	PL 1972-175421	19721019
	PL 92392	P	19770430	PL 1972-175423	19721019
	NO 136842	B	19770808	NO 1972-3756	19721019
	RO 68647	B	19790710	RO 1972-80265	19721019
	RO 68647	P	19800415		
	RO 68646	B	19790715	RO 1972-80264	19721019
	RO 68646	P	19800315		
	RO 68648	B	19790715	RO 1972-80266	19721019
	RO 68648	P	19800315		
	RO 74822	P	19800930	RO 1972-72570	19721019
	JP 48049777	A2	19730713	JP 1972-105135	19721020
	JP 51025032	B4	19760728		
	SU 553931	D	19770405	SU 1973-1985248	19731228
	SU 499807	D	19760115	SU 1973-1982651	19731229
	SU 576934	D	19771015	SU 1973-1982650	19731229
	RO 74822	P	19810924	RO 1975-72570	19751019
PRAI	DE 1971-2152230		19711020		

AB About 20 title compds. [I; R = H or Me; R1 = e.g. Pr, CH2SEt, OCH2CH2OMe, SCHMe2, or cyclohexylmethyl; A = (6-chloro)-8-chromanyl, 9-homochromanyl, 5-chloro-2-methyl-7-benzo[b]furyl, or Y with Q = O or S; R2 = 2- or 3-Me; R3 = H, 4- or 5-Me, 5-OMe, or 5-Cl] and one 1-phenethylbiguanide salt, useful as antidiabetics, were prepd. by several methods. Thus, YCOCl (Q = O, R2 = 2-Me, R3 = 5-OMe) reacted with 4-(2-aminoethyl)-N-[5-cyclohexylmethyl)-2-pyrimidinyl]benzenesulfonamide-HCl in aq. NaOH at pH 12 for >1 hr to give 70.7% I (X = p-C6H4, A = Y, Q = O, R = H, R2 = cyclohexylmethyl, R2 = 2-Me, R3 = 5-OMe). 2-Amino-5-isopropoxypyrimidine reacted with the corresponding benzenesulfonyl Cl in pyridine 4 hr at room temp. and on the steam bath giving 33% I (X = p-C6H4, A = Y, Q = O, R = H, R1 = OCHMe2, R2 = 2-Me, R3 = 5-Cl). Isocaproaldehyde and COCl2 were refluxed in CH2Cl2 and DMF 4 hr, and the reaction product was refluxed with the corresponding benzenesulfonylguanidine in 30% MeONa 12 hr to give I (X = p-C6H4, A = Y, Q = O, R = H, R1 = CH2CHMe2, R2 = 2-Me, R3 = 5-Cl) (II). 5-Isobutyl-2-(trimethylammonio)pyrimidine chloride reacted with the corresponding benzenesulfonamide Na salt in AcNMe2 .apprx.20 hr at room temp. to give II.

IT **42074-85-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 42074-85-1 CAPLUS

CN 2H-1-Benzopyran-8-carboxamide, 3,4-dihydro-N-[1,2,3,4-tetrahydro-7-[[[5-[(1-methylethyl)thio]-2-pyrimidinyl]amino]sulfonyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 57 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 1973:111008 CAPLUS
DN 78:111008
TI [2-(Acylamino)-1,2,3,4-tetrahydro-7-naphthylsulfonyl]ureas
IN Heerdt, Ruth; Huebner, Manfred; Schmidt, Felix Helmut; Thiel, Max; Aumueller, Walter
PA Boehringer, Mannheim G.m.b.H.
SO Ger. Offen., 17 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2135805	A1	19730208	DE 1971-2135805	19710717
	GB 1336983	A	19731114	GB 1972-32364	19720711
	FR 2146260	A1	19730302	FR 1972-25217	19720712
	SE 382632	B	19760209	SE 1972-9167	19720712
	CH 577468	A	19760715	CH 1975-16011	19720712
	CH 583187	A	19761231	CH 1972-10482	19720712
	AT 320661	B	19750225	AT 1972-6093	19720714
	AT 324350	B	19750825	AT 1973-9454	19720714
PRAI	DE 1971-2135805		19710717		

AB Nineteen title compds. [I, e.g. R = 2,5-MeOMeC6H3, 2,5-MeOFC6H3, 2,5-(MeO)2C6H3, 2,5-EtOClC6H3, 3-(.beta.-methoxyethoxy)-2-thienyl, fluoren-9-ylmethyl, 5-methyl-3-isoxazolyl; R1 = Bu, cyclopentyl, 4-methylcyclohexyl, 3-cyclohexenyl, 1-adamantyl, or 4-methylpiperidino], useful as hypoglycemics, were prepd. by reaction of II with OCNR1 or of III with H2NR1. I (R = 5-methyl-3-isoxazolyl, R1 = cyclohexyl) was prepd. by adding 5-methylisoxazole-3-carbonyl chloride to N-(2-amino-1,2,3,4-tetrahydro-7-naphthylsulfonyl)-N'-cyclohexylurea.

IT **40153-63-7P 40153-73-9P 40153-74-0P**
40153-83-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 40153-63-7 CAPLUS
CN 2-Thiophenecarboxamide, 3-(2-methoxyethoxy)-N-[1,2,3,4-tetrahydro-7-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 40153-73-9 CAPLUS
CN 2-Thiophenecarboxamide, 3-ethoxy-N-[1,2,3,4-tetrahydro-7-[[[[(4-methoxycyclohexyl)amino]carbonyl]amino]sulfonyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 40153-74-0 CAPLUS
CN Carbamic acid, [[7-[[(3-ethoxy-2-thienyl)carbonyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 40153-83-1 CAPLUS
CN 3-Isoxazolecarboxamide, N-[7-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-5-methyl- (9CI) (CA INDEX NAME)



IT **40153-75-1**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with Et chloroformate)
RN 40153-75-1 CAPLUS
CN 2-Thiophenecarboxamide, N-[7-(aminosulfonyl)-1,2,3,4-tetrahydro-2-naphthalenyl]-3-ethoxy- (9CI) (CA INDEX NAME)



Intermediate. R^2 & R^3 are not $-SO_2NH_2$ in the claims.

IT **40153-64-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with isocyanates)
RN 40153-64-8 CAPLUS
CN 2-Thiophenecarboxamide, N-[7-(aminosulfonyl)-1,2,3,4-tetrahydro-2-

naphthalenyl]-3-(2-methoxyethoxy)- (9CI) (CA INDEX NAME)



L4 ANSWER 58 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 1973:4276 CAPLUS
DN 78:4276
TI 4-[.beta.-(Quinoline-8-carboxamido)ethyl]-N-(2-pyrimidinyl)benzenesulfonamides
IN Weyer, Rudi; Aumueller, Walter; Schweitzer, Roland; Weber, Helmut; Huebner, Manfred
PA Farbwerke Hoechst A.-G.
SO Ger. Offen., 15 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2107557	A	19721005	DE 1971-2107557	19710217
	ES 399627	A1	19750616	ES 1972-399627	19720210
	NL 7201836	A	19720821	NL 1972-1836	19720211
	BE 779372	A1	19720816	BE 1972-113969	19720215
	AU 7238979	A1	19730816	AU 1972-38979	19720215
	US 3816424	A	19740611	US 1972-226530	19720215
	DK 132223	B	19751110	DK 1972-692	19720215
	FR 2125514	A5	19720929	FR 1972-5188	19720216
	FR 2125514	B1	19750425		
	ZA 7201018	A	19721227	ZA 1972-1018	19720216
	AT 7201260	A	19750215	AT 1972-1260	19720216
	AT 326128	B	19751125		
	AT 7407505	A	19750215	AT 1972-750574	19720216
	AT 7407504	A	19750215	AT 1972-750474	19720216
	CA 963009	A1	19750218	CA 1972-134867	19720216
	AT 326132	B	19751125	AT 1972-326132	19720216
	AT 326131	B	19751125	AT 1972-326131	19720216
	SE 385886	B	19760726	SE 1972-1874	19720216
	CH 578554	A	19760813	CH 1972-2196	19720216
	CH 579070	A	19760831	CH 1975-8211	19720216
	CH 579071	A	19760831	CH 1975-8212	19720216
	GB 1377793	A	19741218	GB 1972-7398	19720217
	AT 7407503	A	19770615	AT 1974-7503	19740917
	AT 341528	B	19780210		
	CH 605912	A	19781013	CH 1975-8210	19750216
PRAI	DE 1971-2107557		19710217		
	AT 1972-1260		19720216		

AB Seventeen title compds. (I, n = 0 or 2; R = H or Me; R1 = Me2CHCH2, Et, Pr, Bu, EtO, Ph, cyclohexyl, Me2CHCH2O, Me2CH, or EtSCH2; R2 = H, Cl, or Br), useful as hypoglycemic agents, were prepd. by reaction of the corresponding (quinolinecarboxamido)benzenesulfonyl chlorides with 2-aminopyrimidines; or of the quinolinecarbonyl chloride with 4-(.beta.-aminoethyl)-N-(2-pyrimidinyl)benzenesulfonamides.
IT **39268-67-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 39268-67-2 CAPLUS
CN 8-Quinolinecarboxamide, 6-chloro-N-[1,2,3,4-tetrahydro-7-[[[5-(2-methylpropyl)-2-pyrimidinyl]amino]sulfonyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)


Cl
N
O
C
NH
O
S
O
NH
N
N
Bu-i

L4 ANSWER 59 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 1972:488182 CAPLUS
DN 77:88182
TI Chemotherapeutic nitroheterocycles. XI. Indanylamides and indanylesters of 5-nitrofurancarboxylic acids and analogous compounds as antimicrobial agents
AU Albrecht, R.; Kessler, H. J.
CS Dep. Arzneimittelchem., Schering A.-G., Berlin, Fed. Rep. Ger.
SO Chimica Therapeutica (1972), 7(1), 9-13
CODEN: CHTPBA; ISSN: 0009-4374
DT Journal
LA English
AB Esters and amides of 5-nitrofurancarboxylic and acrylic acids I (Q = Q1, R = H, 4-Me, 6-Me, 6-MeO, n = 0.1; X = O, NH; Z = CH2, CH2CH2, CH2O) and I (n = 1, Q = 5,6-dimethoxy-1-indanylamino, 1-oxo-7-indanyloxy, 5,6,7,8-tetrahydro-2-naphthylamino, 5-oxo-5,6,7-8-tetrahydro-2-naphthylamino, 3,4-methylenedioxyanilino, 1-indolinyl, 4-oxo-1,2,3,4-tetrahydroquinolyl, 7-methoxy-4-oxo-1,2,3,4-tetrahydroquinolyl) were prepd. for biocidal testing by acylation of the amine or alc. with the acid chloride and Et3N. I (n = 1, Q = 1-oxo-7-indanyloxy) was prepd. in 41% yield from the acid chloride in pyridine and had a min. inhibitory concn. of 2.1 .mu.g/ml against Candida albicans. I (n = 1, Q = 3,4-methy-lenedioxyanilino) had min. inhibitory concns. against Staphylococcus aureus 1.6, Escherichia coli 0.8 and Mycobacterium tuberculosis 1.6 .mu.g/ml. Several I were active in vitro against Trichomonas vaginalis but not in vivo.
IT **37542-57-7P 37542-58-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 37542-57-7 CAPLUS
CN 2-Furancarboxamide, 5-nitro-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 37542-58-8 CAPLUS
CN 2-Furancarboxamide, 5-nitro-N-(1,2,3,4-tetrahydro-6-methoxy-1-naphthalenyl)- (9CI) (CA INDEX NAME)


NO2
O
C
O
NH
OMe

L4 ANSWER 60 OF 60 CAPLUS COPYRIGHT 2003 ACS
AN 1972:99694 CAPLUS
DN 76:99694
TI Blood sugar-lowering sulfonylamino pyrimidines
IN Hagedorn, Adolf; Huebner, Manfred; Heerdt, Ruth; Schmidt, Felix Helmut; Aumueller, Walter
PA Boehringer Mannheim G.m.b.H.
SO Ger. Offen., 18 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2022746	A	19711202	DE 1970-2022746	19700509
	CH 563992	A	19750715	CH 1971-6640	19710505
	CH 563993	A	19750715	CH 1975-3593	19710505
	CH 563994	A	19750715	CH 1975-3594	19710505
	CH 572913	A	19760227	CH 1975-3595	19710505
	GB 1291661	A	19721004	GB 1971-1291661	19710506
	FR 2100641	A5	19720324	FR 1971-16514	19710507
	FR 2100641	B1	19750418		
	AT 306728	B	19730425	AT 1971-3996	19710507
	AT 306737	B	19730425	AT 1972-4102	19710507
	AT 306738	B	19730425	AT 1972-4104	19710507
	AT 307428	B	19730525	AT 1972-4103	19710507
PRAI	DE 1970-2022746		19700509		

AB Approx. 20 title compds. [I, R = 5,2-Me(MeO)C6H3, 5,2-Cl(MeO)C6H3, 5,2-Cl(EtO)C6H3, 5,2-F(MeO)C6H3, 5,2-Br(MeO)C6H3, 9-fluorenylmethyl, 2-MeOC6-H4, 3-ethoxy-2-thienyl, 3-(2-methoxyethoxy)-2-thienyl; R1 = Me2CHO, Pr, MeOCH2, Me2CHS, Me2CHCH2, PhCH2, MeOCH2CH2, cyclohexyl, cyclohexylmethyl, cyclohexyloxy, Ph; R2 = H, Me; R1R2 = (CH2)4] were prepd. -(2-Methoxy-5-methylbenzamido)-1,2,3,4-tetrahydronaphthalene-7-sulfonyl chloride was treated with 2-amino-5-isopropoxypyrimidine in abs. pyridine to give I [R = 5,2-Me(MeO)C6H3, R1 = Me2CHO, R2 = H]. -Fluorenylacetyl chloride was treated with 2-amino-N-(5-isobutyl-2-pyrimidinyl)-1,2,3,4-tetrahydronaphthalene-7-sulfonamide to give 2-(9-fluorenylacetamido)-N-(5-isobutyl-2-pyrimidinyl)-1,2,3,4-tetrahydronaphthalene-7-sulfonamide. -(5-Chloro-2-methoxybenzamido)-1,2,3,4-tetrahydronaphtha-lene-7-sulfonamide Na salt and 5-isobutyl-2-trimethylammonio-pyrimidine chloride gave I [R = 5,2-Cl(MeO)C6H3, R1 = Me2CHCH2, R2 = H].

IT **35265-95-3P 35265-96-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 35265-95-3 CAPLUS
CN 2-Thiophenecarboxamide, 3-ethoxy-N-[1,2,3,4-tetrahydro-7-[[[5-(2-methylpropyl)-2-pyrimidinyl]amino]sulfonyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 35265-96-4 CAPLUS
CN 2-Thiophenecarboxamide, 3-(2-methoxyethoxy)-N-[1,2,3,4-tetrahydro-7-[[[5-(2-methylpropyl)-2-pyrimidinyl]amino]sulfonyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)



```
=> d his

     (FILE 'HOME' ENTERED AT 14:07:40 ON 06 MAR 2003)

     FILE 'REGISTRY' ENTERED AT 14:07:45 ON 06 MAR 2003
L1             STRUCTURE UPLOADED
L2               2 S L1 SSS SAM
L3             319 S L1 SSS FUL

     FILE 'CAPLUS' ENTERED AT 14:08:41 ON 06 MAR 2003
L4              60 S L3

     FILE 'CAOLD' ENTERED AT 14:11:04 ON 06 MAR 2003

=> s l3
L5               0 L3

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.40     422.99

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00     -39.06

STN INTERNATIONAL LOGOFF AT 14:11:18 ON 06 MAR 2003
```